Post-Translational Control of Retinoblastoma Protein Phosphorylation by Stafford, Paul M
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
9-25-2014 12:00 AM 
Post-Translational Control of Retinoblastoma Protein 
Phosphorylation 
Paul M. Stafford 
The University of Western Ontario 
Supervisor 
Dr. Fred Dick 
The University of Western Ontario 
Graduate Program in Biochemistry 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Paul M. Stafford 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Biochemistry Commons, and the Molecular Biology Commons 
Recommended Citation 
Stafford, Paul M., "Post-Translational Control of Retinoblastoma Protein Phosphorylation" (2014). 
Electronic Thesis and Dissertation Repository. 2449. 
https://ir.lib.uwo.ca/etd/2449 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
  
POST-TRANSLATIONAL CONTROL OF RETINOBLASTOMA PROTEIN 
PHOSPHORYLATION 
 
(Thesis format: Integrated Article) 
 
 
 
by 
 
 
 
Paul Stafford 
 
 
 
 
Graduate Program in Biochemistry 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Paul Stafford 2015 
i 
 
Abstract 
The retinoblastoma tumor suppressor protein (pRB) functions through multiple 
mechanisms to serve as a tumor suppressor. pRB has been well characterized to be 
inactivated through phosphorylation by CDKs. pRB dephosphorylation and activation is 
a much less characterized aspect of pRB function. In this thesis, I detail work to study the 
post translational control of pRB phosphorylation. Here I  present  work  detailing  efforts  
to  generate  a  gene targeted  mouse  which  disrupts  PP1  binding  to  the  C-terminus  
of pRB,  allowing  for  detailed  study  of  the  mechanisms  of  pRB dephosphorylation. 
This work also details an examination of acetylation in the C-terminus of pRB, which 
disrupts CDK phosphorylation of pRB. I generated a site specific antibody to examine 
K873/K874 acetylation, and carried out characterization of this set of post-translational 
modifications. This work highlights the complex mechanisms surrounding pRB 
phosphorylation state and regulation of pRB activation. 
 
Keywords: pRB, post-translational modifications, DNA damage, dephosphorylation, 
acetylation, Protein Phosphatase 1, gene targeted mouse 
  
ii 
 
Co-Authorship Statement  
All chapters in this thesis were written by Paul Stafford and edited by Dr. Fred Dick.  
  
iii 
 
Acknowledgments 
Grad school has been an exciting opportunity not only to learn how to become a better 
scientist and researcher, but in general to learn more about strengths and my weaknesses. 
My time in grad school has been filled with many highs and lows but this experience 
could not be what it was without the support of everyone along the way. 
First I would like to thank my supervisor Dr. Fred Dick for his support, guidance and 
advice along the many highs and lows of graduate school. He provided me with not only 
an exemplary model of what it takes to be a successful researcher, but a model of what it 
takes to be successful in any walk of life. His willingness to always challenge me to 
become a better researcher and to instill confidence in me will always be remembered.  
I would also like to thank my supervisory committee consisting of Dr. Joe Torchia and 
Dr. Gabe DiMattia for their advice and guidance over the years. As well I would like to 
thank my examination committee of Dr. David O‟Gorman, Dr. Shawn Li and Dr. John 
DiGuglielmo for their excellent questions and suggestions in the preparation of this 
thesis. 
Next, I would like to thank all of the Dick lab members I have had the pleasure of 
working with over the last few years. Each of you has not only helped me along my 
progression through graduate school through advice, insights, and criticisms of my 
scientific work, but each of you has made graduate school a memorable and enjoyable 
experience in my life. I would also like to thank friends, colleagues and all the staff of 
both the LRCP and Western I have come in contact with over the years for further 
enriching my graduate experience. 
Finally, I would like to thank my friends and family for the countless amounts of 
support and patience over my time in graduate school. Your unconditional support, 
patience and belief in me over the high and lows of graduate school has been the one 
constant over this entire experience. 
iv 
 
Table of Contents 
Abstract ................................................................................................................................ i 
Co-Authorship Statement.................................................................................................... ii 
Acknowledgments.............................................................................................................. iii 
Table of Contents ............................................................................................................... iv 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Abbreviations .......................................................................................................... x 
Chapter 1 ............................................................................................................................. 1 
1 Introduction .................................................................................................................... 1 
1.1 Classical Roles of pRB ........................................................................................... 1 
1.1.1 pRB Regulates the G1 to S Transition of the Cell Cycle ............................ 1 
1.1.2 The Pocket Protein Family.......................................................................... 3 
1.1.3 A Model of pRB and E2Fs at the G1-S Transition ..................................... 3 
1.1.4 Regulation of Heterochromatin through LXCXE interactions with 
Pocket Proteins............................................................................................ 4 
1.2 Post G1-S Roles of the Retinoblastoma Protein are Tumor Suppressive ............... 6 
1.2.1 A pRB/E2F1 “Specific” Interaction that Exists Outside of G1 .................. 7 
1.2.2 LXCXE Interactions with pRB Beyond G1................................................ 9 
1.3 Post-Translational Modifications of pRB ............................................................. 10 
1.3.1 CDK Phosphorylation of pRB .................................................................. 10 
1.3.2 Acetylation of pRB ................................................................................... 14 
1.4 pRB Dephosphorylation........................................................................................ 15 
1.4.1 Regulation of pRB Dephosphorylation in the Cell Cycle ......................... 15 
1.4.2 Regulation of pRB Dephosphorylation in Conditions of Cellular Stress . 16 
v 
 
1.4.3 A Specific and Direct Interaction of PP1 with the C-Terminus of pRB ... 16 
1.5 Hypothesis and Objectives .................................................................................... 18 
1.6 References ............................................................................................................. 19 
Chapter 2 ........................................................................................................................... 33 
2 Methods ........................................................................................................................ 33 
2.1 Plasmids ................................................................................................................ 33 
2.2 Plasmid Construction ............................................................................................ 33 
2.2.1 psCodon1-GST-RBLP-K873/K874A ....................................................... 33 
2.2.2 pRBΔPP1 Targeting Vector Construction ................................................ 33 
2.3 PCR and Primers ................................................................................................... 35 
2.3.1 PCR Conditions to Create GST-RB LP K873/K874A (GST 
Expression) ............................................................................................... 35 
2.4 Antibody Generation and Purification .................................................................. 38 
2.5 Enzyme Linked Immunosorbent Assay ................................................................ 39 
2.6 Peptide SPOT Membrane Assay ........................................................................... 40 
2.7 Cell Culture ........................................................................................................... 44 
2.8 Recombinant Protein Purification ......................................................................... 44 
2.9 GST Pulldown Binding Experiments.................................................................... 45 
2.10 Western Blotting and Immunoprecipitations ....................................................... 45 
2.11 In Vitro Acetylation Assay ................................................................................... 46 
2.12 In Vitro Kinase Assay .......................................................................................... 48 
2.13 Immunopurified-Kinase Assay ............................................................................ 48 
2.14 mESC Cell Culture ............................................................................................... 49 
2.15 Southern Blot Screening ...................................................................................... 49 
2.15.1 Southern Blot: Labeling and Purifying the Probe ..................................... 50 
2.16 References ............................................................................................................ 52 
vi 
 
Chapter 3 ........................................................................................................................... 54 
3 Study of pRB K873/K874 Acetylation ........................................................................ 54 
3.1 Analysis of pRB Antibody Specificity in the pRB C-Terminus ........................... 54 
3.2 Generation and Characterization of Anti-Acetyl K873/K874 pRB Antibodies ... 55 
3.3 Acetyl K873/K874 pRB Antibody Specifically Detects Acetylated 
Recombinant pRB ................................................................................................. 61 
3.4 CDK Phosphorylation of pRB May Be Affected by pRB K873/K874 
Acetylation ............................................................................................................ 64 
3.5 Acetylation of pRB at K873 and K874 is Unable to be Detected In Vivo ............ 65 
3.6 References ............................................................................................................. 73 
Chapter 4 ........................................................................................................................... 74 
4 The Rb1ΔPP1 Mouse ...................................................................................................... 74 
4.1 Generation of Rb1ΔPP1 Gene Targeted Mouse Model ........................................ 74 
4.2 Southern Blot Screening Lead to a Small Selection of Potential Targeted 
Clones ................................................................................................................... 75 
4.3 Confirmation Screening of Candidate mESC Clones Showed No Correctly 
Targeted Clones .................................................................................................... 79 
4.4 References ............................................................................................................. 82 
5 Discussion .................................................................................................................... 83 
5.1 Summary of Findings ............................................................................................ 83 
5.2 Acetylation of pRB ............................................................................................... 84 
5.3 Lack of K873/K874 Acetylation of pRB In Vivo Under DNA Damage with 
Acetyl-K873/K874 Antibodies ............................................................................. 86 
5.4 Attempted Creation of the Rb1ΔPP1 Gene Targeted Mouse ............................... 88 
5.5 Conclusions ........................................................................................................... 90 
5.6 References ............................................................................................................. 91 
Curriculum Vitae .............................................................................................................. 93 
vii 
 
List of Tables  
Table 2.1 Description of Plasmids Used and Created....................................................... 34 
Table 2.2: List of Primers ................................................................................................. 37 
Table 2.3: List of Human and Mouse pRB Peptides for SPOT Array .............................. 41 
Table 2.4: Description of Antibodies ................................................................................ 47 
 
viii 
 
List of Figures  
Figure 1.1: Structures of the Pocket Proteins...................................................................... 2 
Figure 1.2:  Model of pRB function in the Regulation of the G1-S transition of the cell 
cycle .................................................................................................................................... 5 
Figure 1.3: pRB has a Unique Interaction with E2F1 ......................................................... 8 
Figure 1.4: CDK Phosphorylation Sites and Lysine Acetylation Sites on pRB ............... 11 
Figure 1.5: pRB Functions Throughout the Cell Cycle .................................................... 17 
Figure 2.1: Schematic of the Rb1ΔPP1 Targeting Construct ............................................ 36 
Figure 3.1: Characterization of pRB Antibodies............................................................... 56 
Figure 3.2: Schematic of pRB Antibody Epitopes on Human and Mouse pRB ............... 57 
Figure 3.3: Generation of an Antibody Against Acetylated pRB ...................................... 59 
Figure 3.4: ELISA Analysis Demonstrating Specificity of Anti-Acetyl K873/K874 pRB 
Antibody ........................................................................................................................... 60 
Figure 3.5: Anti-Acetyl-pRB Antibody Specifically Detects Modified GST-pRB LP .... 62 
Figure 3.6: Anti-Acetyl K873/K874 pRB Antibody Specifically Detects Modified GST-
pRB LP.............................................................................................................................. 63 
Figure 3.7: CDK Phosphorylation of Acetylated GST-pRB LP ....................................... 66 
Figure 3.8: Schematic of Immunopurified Acetyl K873/K874-pRB Substrate Kinase 
Assay ................................................................................................................................. 67 
Figure 3.9: Acetylation of pRB Inhibits CDK Phosphorylation ....................................... 68 
Figure 3.10: Unable to Detect Ac-pRB in Asynchronous Cells ....................................... 70 
ix 
 
Figure 3.11: Unable to Detect Ac-K873/K874 pRB Following DNA Damage ................ 71 
Figure 3.12: Unable to Detect Ac-K873/K874 pRB Binding to E2F1 ............................. 72 
Figure 4.1: The Rb1
ΔPP1
 Mutation and Schematic of Targeting for Rb1
ΔPP1
 Gene Targeted 
Mice .................................................................................................................................. 76 
Figure 4.2: Schematic of Targeting for Rb1
ΔPP1
 Mutation in the Rb1 Locus .................... 77 
Figure 4.3: Screening of mESCs with Southern Blotting for Incorporation of the Rb1
ΔPP1
 
into the Rb1 Locus ............................................................................................................ 78 
Figure 4.4: Single Integration of the Neomycin Selection Cassette in Candidate Clones 80 
Figure 4.5: Confirmation Southern Blot of Three Potentially Targeted mESC Clones ... 81 
 
  
x 
 
List of Abbreviations 
°C: Degrees Celsius  
µg: microgram  
µL: microliter 
µM: micromolar 
32
P: Phosphorus-32 radioisotope of phosphorus 
A: Alanine amino acid 
APC:  Anaphase promoting complex 
ATP: adenosine triphosphate 
bp: Base pair 
BSA: Bovine serum albumin 
CDK: Cyclin dependent kinase 
CKI: Cyclin dependent kinase inhibitor 
CO2: carbon dioxide 
CRF: Chromatin regulatory factor 
C-terminal: carboxy terminal 
DBD: DNA binding domain 
DDR: DNA damage response 
DMEM: Dulbecco‟s Modified Eagle Medium 
DMZ: dimerization domain 
xi 
 
DNA: deoxyribonucleic acid 
DP: Differentiation Related Transcription Factor-1 polypeptide-1 
DTT: Dithiothreitol 
E: Embryonic day 
E2F: E2 promoter binding factor 
E7: early protein 7 
EDTA: Ethylene diamine tetraacetic acid 
ELISA: enzyme-linked immune sorbent assay 
F: Phenylalanine amino acid 
FBS: fetal bovine serum 
xG: Gravity  
G1: gap 1 phase of the cell division cycle 
G2: gap 2 phase of the cell division cycle 
GSE: Gel shift extraction buffer  
GST: Glutathione S-transferase 
GST-RB-LP: GST tagged large pocket domain of pRB   
HA: Hemaglutinnin 
HAT: histone acetyl transferase 
HCl: hydrochloric acid 
hESC: Human Embryonic stem cell 
xii 
 
Hr(s): Hour(S) 
IF: Immunofluorescence  
IgG: immunoglobulin G  min: minutes 
IN: input   
IP: Immunoprecipitation  
IPTG:  Isopropyl !-D-1-thiogalactopyranoside 
K: Lysine amino acid 
kb: Kilo base 
KCl: Potassium Chloride 
kD: Kilo dalton  
LB: Luria Broth 
LXCXE: Leucine-any amino acid-cysteine-any amino acid-glutamate  
M: mitosis (when referring to the phases of the cell division cycle) 
MB: marked box 
MEF: mouse embryonic fibroblast 
mESC:  Mouse Embryonic stem cell 
MgCl2: magnesium chloride 
min: minutes 
mL: milliliter 
N/A: not applicable 
xiii 
 
Na3VO4: Sodium Orthovanadate  
NaCl: Sodium Chloride 
NaF: Sodium Fluoride 
NaN3: Sodium azide 
ng: nanogram 
N-terminus: Amino Terminus 
p107: Retinoblastoma-like protein 1 
p130: Retinoblastoma-like protein 2 
PAGE: Polyacrylamide gel electrophoresis 
PBS: Phosphate buffered saline  
pCAF: p300-CBP associated factor 
PCR: polymerase chain reaction 
PMSF: Phenylmethylsufonylfluuride 
PP1: protein phosphatase 1 
PP2A: protein phosphatase 2A 
pRB: Human  Retinoblastoma tumor suppressor protein   
pRb: Mouse Retinoblastoma tumor suppressor protein 
R: Arginine 
RB1: Human retinoblastoma tumor suppressor gene  
Rb1: Mouse retinoblastoma tumor suppressor gene  
xiv 
 
S: DNA synthesis phase of the cell division   
SDS: Sodium dodecyl sulfate 
TA: transactivation domain 
Taq: Thermus aquaticus 
TBS: Tris-Buffered Saline 
TBST: Tris-buffered Saline with Tween20 
TCEP: tris (2-carboxyethyl) phosphine 
WB: Western blot  
WB: western blot 
Δ: lacking 
ΔG: General Site Mutation 
ΔL: ΔLXCXE mutation 
ΔPP1: Protein Phosphate 1 Binding Site mutation 
ΔS: Specific Site Mutation
1 
 
Chapter 1  
1 Introduction  
1.1 Classical Roles of pRB  
1.1.1 pRB Regulates the G1 to S Transition of the Cell Cycle 
The retinoblastoma tumor suppressor protein (pRB) was identified as the product of the 
retinoblastoma susceptibility gene RB1, with mutations in this gene being the cause of 
inherited cancers of the retina which are termed retinoblastomas (Friend et al., 1986; Lee 
et al., 1987). pRB was classified as a tumor suppressor before it was apparent what the 
biological function of this protein was through evaluation of the genetics of 
retinoblastoma patients as well as study of oncogenic viruses (Dyson et al., 1989; 
Knudson, 1971; Murphree and Benedict, 1984; Whyte et al., 1988). Initial functional 
studies of pRB determined that pRB plays a critical role in regulating the cell cycle, by 
controlling the progression of the cell from G1 into the S-phase (DeCaprio et al., 1989). 
This regulation of the cell cycle is imparted through the regulation of a family of 
transcription factors known as the E2Fs through a physical interaction (Chellappan et al., 
1991; Hiebert et al., 1992a; Lees et al., 1993) which was demonstrated to occur through 
the “small pocket” domain (res. 379-792) and the C-terminus of pRB (res. 793 – 
928)(Qin et al., 1992)(Fig. 1.1). The E2Fs induce a transcriptional program at the G1-S 
transition that functions to drive the entry into S-phase and initiate DNA synthesis (Blake 
and Azizkhan, 1989; Dalton, 1992; Hiebert et al., 1989; Thalmeier et al., 1989). The 
expression of multiple different E2F family members is able to drive cells into S phase 
(DeGregori et al., 1997; Johnson et al., 1993) highlighting the importance of the E2F 
family in mediating the G1-S transition. The physical interaction though between pRB 
and E2Fs was found to lead to negative regulation of E2F target genes (Helin et al., 1993; 
Hiebert et al., 1992a), thus giving a mechanism to pRB‟s ability to regulate the G1-S 
transition of the cell cycle and a basis for pRB‟s tumor suppressive properties.  
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Figure 1.1: Structures of the Pocket Proteins 
The pocket proteins are defined by the small pocket region consisting of the A and B 
cyclin fold domains that are conserved across all three members. The LXCXE binding 
cleft for LXCXE motif containing proteins is highly conserved across the pocket protein 
family. pRB is primarily distinguished structurally from the other pocket proteins 
members by a unique interaction with E2F1 in the C-terminus. The C-terminus of pRB 
also contains overlapping binding sites for Cyclin-CDKs and PP1. The other pocket 
protein family members, p107 and p130, are distinguished from pRB by the presence of a 
Cyclin-CDK binding domain in the small pocket itself and an insert in the B part of the 
small pocket. The N-terminus of p107 and p130 also contain a CDK inhibitory domain 
which is unique to these two family members. 
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1.1.2 The Pocket Protein Family 
The pocket protein family consists of three highly related proteins, which are pRB, and 
the gene products of RBL1 and RBL2, p107 and p130 (Fig. 1.1) (Cobrinik et al., 1993; 
Ewen et al., 1991; Hannon et al., 1993; Mayol et al., 1993).  Each family member 
contains a highly conserved region called the “small pocket” which is made up of an A 
and B domain consisting of single cyclin-like folds, which are separated by a flexible 
linker region(Lee et al., 1998) (Fig 1.1). This domain serves as the minimal binding 
domain of many viral oncoproteins(Hu et al., 1990) and is sufficient to repress 
transcription through interactions with E2Fs (Chow et al., 1996; Chow and Dean, 1996; 
Sellers et al., 1995). Viral oncoprotein binding to the small pocket has been attributed to 
the LXCXE motif. Crystallography has demonstrated that the LXCXE motif contained in 
viral oncoproteins makes contact with a shallow groove in the B domain of the small 
pocket (Lee and Cho, 2002; Lee et al., 1998) known as the LXCXE binding cleft. The 
small pocket, though being highly conserved across the family members and different 
species, still has subtle differences between the different family members, with p107 and 
p130 having insertions in the B domain and a longer linker relative to pRB(Classon and 
Dyson, 2001; Hurford et al., 1997; Mulligan and Jacks, 1998). The “large pocket” 
consists of the small pocket as well as the C-terminus and is the minimal growth 
suppressing domain and is sufficient to interact with the E2F family of transcription 
factors and inhibit E2F target gene transcription(Bremner et al., 1995; Hiebert, 1993; 
Hiebert et al., 1992b; Qin et al., 1992; Yang et al., 2002). This interaction is mediated 
through a physical association of the large pocket with the transactivation domain of the 
E2F (Lee et al., 2002). Specific amino acids in the transactivation domain of E2F make 
conserved contacts with amino acids in the A domain. Further contacts with the largely 
unstructured C-terminus of the large pocket further act to stabilize this interaction with 
E2Fs, leading to an inhibition of E2F transcriptional activity. 
1.1.3 A Model of pRB and E2Fs at the G1-S Transition 
pRB has been shown to be regulated in a cell cycle dependent manner and as mentioned 
above to be a central regulator of the cell cycle(DeCaprio et al., 1989; Huang et al., 1988; 
Takahashi et al., 1991). Pocket proteins, which lack intrinsic ability to bind DNA, bind to 
4 
 
E2F family members, thus localizing themselves at E2F transcriptional target genes. 
Pocket proteins though display different cell cycle roles due to differential expression and 
preference for specific E2F family members (Classon and Dyson, 2001; Henley and 
Dick, 2012). The localization of pocket proteins at E2F target genes thus enables active 
repression of these genes and prevents progression into the cell cycle. Upon entrance to 
the cell cycle, expression of the retinoblastoma protein increases and pRB localizes to 
E2F target genes, inhibiting the transcriptional activity of E2Fs. This is mediated by 
physically masking their transactivation domain as mentioned above, preventing 
transcription of genes required for progression into S-phase(Hurford et al., 1997; Lavia 
and Jansen-Durr, 1999; Takahashi et al., 2000). Activation of E2Fs, and progression into 
S-phase, is mediated by phosphorylation of pocket proteins in a cell cycle-dependent 
manner by cyclin/cyclin-dependent kinase (CDK) complexes. Mitogen stimulation of 
cells leads to activation of CDK complexes and phosphorylation of the pocket proteins 
(Buchkovich et al., 1989; DeCaprio et al., 1992; Lin et al., 1991; Mihara et al., 1989). 
The phosphorylation of pocket proteins leads to a release of E2F binding, allowing for 
the transactivation of E2F target genes (Burke et al., 2010; Chittenden et al., 1993; 
Mudryj et al., 1991). The activation of CDK complexes occurs in a feed-forward loop 
that is antagonized by CDK inhibitors (CKIs). As a result of a feed forward loop for CDK 
complexes, phosphorylation of pocket proteins is maximized, and thus cells irreversibly 
advance into S-phase (Fig 1.2)(Mittnacht, 1998; Sherr and Roberts, 1999; Sherr, 1994).  
1.1.4 Regulation of Heterochromatin through LXCXE interactions 
with Pocket Proteins 
As mentioned above, pocket proteins contain a highly conserved region in the small 
pocket that facilitates binding of viral oncoproteins, the LXCXE binding cleft. While 
highly conserved in viral oncoproteins, this LXCXE motif also has been found to be 
conserved with a host of cellular proteins and thus are able to bind in the LXCXE binding 
cleft (Dick, 2007). The majority of the proteins that bind through the LXCXE binding 
cleft function in the role of chromatin remodeling factors (CRFs), with notable 
interactions including HDAC1 and Suv39h1(Brehm and Kouzarides, 1999; Brehm et al., 
1998; Nielsen et al., 2001). The association of these CRFs with pocket proteins allows for 
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Figure 1.2:  Model of pRB function in the Regulation of the G1-S transition of the 
cell cycle 
In G1 pRB interacts with the transactivation domain of E2F/DP heterodimer and blocks 
their activation of E2F target genes. pRB-E2F-DP complexes bound to E2F target genes 
are capable of recruiting chromatin remodeling factors (CRFs) to further repress the 
activation of these genes through the generation of a repressive chromatin environment. 
As cells transition through G1 into S phase, cyclin dependent kinases are activated. This 
includes CDK4 and CDK6 with Cyclin D and CDK2 with Cyclin E. Cyclin/CDK 
phosphorylation of pRB phosphorylation leads to the release of E2F/DP heterodimers, 
allowing for active transcription of E2F target genes and progression of the cell into S-
phase. 
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 recruitment of proteins that act to establish a repressive heterochromatin environment, 
allowing for establishment of heterochromatin at E2F target genes which have a pocket 
protein associated with them. This adds a further level of repression and regulation of 
E2F target genes in regards to our model of the pRB/E2F G1-S transition presented in 
Figure 1.2.  
 While CRFs are a predominant class of proteins that have interactions mediated 
through the LXCXE binding cleft, other classes of proteins bind and act through LXCXE 
interactions with pRB including those involved with DNA replication and 
differentiation(Chan et al., 2001a; Dick, 2007; Miyake et al., 2000; Nguyen et al., 2004). 
The preponderance of different protein complexes that interact with pRB through the 
LXCXE binding cleft are important to control of cell proliferation, though not through 
direct regulation of E2F target gene transcription as a gene targeted mouse developed in 
our lab, the Rb1ΔLXCXE (Rb1ΔL), which ablates the LXCXE binding cleft in pRB, do 
not have upregulated E2F target genes and are viable, fertile and born at nearly the 
expected Mendelian ratios(Isaac et al., 2006). Mouse embryonic fibroblasts (MEFs) from 
Rb1
ΔL/ΔL
 mice though fail in properly establishing a full senescence program and seem to 
be defective for binding to PML proteins which facilitate the senescence program(Talluri 
and Dick, 2014; Talluri et al., 2009). Rb1
ΔL/ΔL 
mice also exhibit defects in the ability to 
respond to TGF-β signalling during breast development (Francis et al., 2009). From these 
results, we can gather that a host of multimeric complexes centered on pRB/E2F 
interactions exist and that the proper regulation of these interactions may be critical in 
understanding pRB‟s ability to actively repress E2F target genes and lead to a stable cell 
cycle arrest.  
1.2 Post G1-S Roles of the Retinoblastoma Protein 
are Tumor Suppressive 
As mentioned above, the first regulatory paradigm discovered for pRB for regulation of 
the cell cycle is in regards to its role in mediating the G1-S transition in the cell cycle. 
Recent work in our lab and others have begun to discover other regulatory roles of pRB 
beyond the G1-S transition that may contribute to the tumour suppressive functions of 
pRB and appear to be unique to pRB alone. 
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1.2.1 A pRB/E2F1 “Specific” Interaction that Exists Outside of G1 
As described above, pRB acts to repress E2F transcription through a physical association 
of the large pocket of pRB with the transactivation domain of E2Fs. Among the activator 
E2Fs, E2F1 demonstrates unique and possibly conflicting functions in regards to the 
other E2Fs. This is highlighted in a mouse genetic model where E2F1 has been ablated, 
which leads to defective apoptosis in thymocytes resulting in a defect in negative 
selection of T-cells (Field et al., 1996). This apoptotic defect is further highlighted as 
mouse genetic models ablating other E2Fs fail to show similar defects in regards to 
apoptosis (Chen et al., 2009; Humbert et al., 2000; Rempel et al., 2000). E2F1 induction 
of apoptosis relies on an induction of p53 and a physical association with a host of pro-
apoptotic genes including p73, Caspase 8, and Bid (Cao et al., 2004; Kowalik et al., 
1995; Nahle et al., 2002; Pediconi et al., 2003; Stanelle et al., 2002; Zhu et al., 1999). 
pRB interestingly has been shown to be localized with E2F1 at these pro-apoptotic 
promoters and localization of pRB and E2F1 across the genome during S-phase has been 
demonstrated through ChiP experiments(Ianari et al., 2009; Wells et al., 2003). Thus 
from overview of this data, pRB/E2F1 complexes seem to act in a unique manner relative 
to the canonical description of pRB/E2F interactions described above. 
Through mutational studies of the large pocket of pRB, it was found that E2F1alone was 
able to bind to the C-terminus of pRB and that this interaction was unique within the 
pocket protein family to pRB/E2F1(Dick and Dyson, 2003). This interaction was found 
to be through distinct binding conformations with the C-terminus of pRB interacting with 
the marked box domain of E2F1(Julian et al., 2008). This interaction of the pRB c-
terminus with the Marked box domain of E2F1 has been distinguished as the “Specific 
site” interaction while the large pocket binding of pRB to E2F1-4 has been distinguished 
as the “General site” (Fig 1.3). Interestingly, recent work has suggested that the specific 
complex is resistant to two canonical methods of disrupting pRB binding to E2Fs, with 
the viral oncoprotein E1A being unable to disrupt this complex (Seifried et al., 2008). 
Furthermore, this specific interaction was demonstrated to be resistant to CDK 
phosphorylation, allowing for a population of E2F1 to be bound by pRB even after 
phosphorylation(Cecchini and Dick, 2011). Interestingly, this complex was demonstrated 
8 
 
   
Figure 1.3: pRB has a Unique Interaction with E2F1 
pRB is able to interact with E2F1 through two distinct interactions. The „General‟ 
interaction is shared by all E2Fs that bind to pRB. This involves the large pocket, (the 
small pocket and the C-terminus), interacting with the transactivation domain of E2Fs. 
The „Specific‟ interaction, which is unique for pRB among the pocket protein family, is 
through residues 825-860 of the pRB C-terminus with the marked box domain of E2F1. 
A -Cyclin A binding domain. DBD- DNA binding domain. DMZ- Dimerization domain. 
MB- Marked box domain. TA- Transactivation domain. 
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 to be able to regulate the expression of p73 in vivo, and to modulate this response in the 
context of DNA damage signaling potentially give a mechanism to explain the pro 
apoptotic roles of pRB and E2F1 mentioned above(Carnevale et al., 2012; Julian et al., 
2008). With the emergence of a multiple unique pRB/E2F1 interaction surfaces that 
appear to have functionally different consequences, understanding the regulation between 
these two unique complexes presents an exciting area for deeper understanding of pRB 
tumour suppressive functions. 
1.2.2 LXCXE Interactions with pRB Beyond G1 
As mentioned above, many classes of proteins bind to pRB through the LXCXE binding 
cleft and help to facilitate a stable arrest in G1 of the cell cycle. As mentioned above, a 
gene targeted mouse model developed in our lab, Rb1
ΔL
, are viable, though exhibit 
defects in scenarios of cell cycle exit including senescence, response to γ-irradiation and 
response to TGF-β signalling(Francis et al., 2009; Talluri et al., 2009). These mice, 
though while not succumbing to spontaneous formation of cancer, interestingly exhibited 
a form of genomic instability with an increase in aneuploidy (Isaac et al., 2006). From 
this study, the aneuploidy that accumulated in Rb1
ΔL
 MEFs was attributed to the fusions 
in the pericentromere of chromatin leading to aberrant progression through mitosis. As 
highlighted above, no defects in E2F target gene expression are observed in Rb1
ΔL
 MEFs, 
including E2F target genes involved in mitosis,  including Mad2 and BubR1, which 
compose the spindle checkpoint(Isaac et al., 2006). While direct effects related to E2F 
transcription were ruled out, recent work from our lab, as well as other investigators have 
revealed that pRB is able to interact with the Condensin II complex subunit Cap-D3 and 
that this interaction is dependent on binding in the LXCXE cleft of pRB(Coschi et al., 
2010; Longworth et al., 2008; Manning et al., 2010). Interestingly this interaction was 
able to mechanistically explain the earlier mentioned defects in pericentromeres of Rb1
ΔL
 
MEFs and that proper regulation of this interaction is required for full pRB mediated 
tumour suppression (Coschi et al., 2010). With these findings, an unknown determinant 
of this mechanism is how in fact pRB localizes to the pericentromere without intrinsic 
ability to bind DNA. Recent observations from our lab have determined that pRB 
localization to the pericentromere of chromatin is dependent on pRB binding to E2F1 
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leading to Condensin II complex recruitment at the pericentromeres (Coschi et al., 2014). 
Furthermore, failure to recruit a complex of pRB/E2F1/Condensin II leads to an increase 
in genomic instability due to replicative stress (Coschi et al., 2014) 
 With the evidence of LXCXE dependent interactions of pRB that persist beyond 
G1 of the cell cycle, one question that persists is how this interaction is retained in an 
LXCXE manner. Prior observations suggest that phosphorylation of pRB by CDKs while 
disrupting pRB/E2F interactions through the general site also disrupt chromatin 
remodelers from binding to the LXCXE binding cleft (Harbour et al., 1999a; Knudsen 
and Wang, 1996). With these observations, speculation in the pRB field remains on how 
the LXCXE dependent interactions with pRB persist past the G1 phase of the cell cycle 
when pRB is extensively phosphorylated. By gaining a further understanding of the 
control and regulation of pRB phosphorylation, this offers a potential means to regulate 
and control these interactions.  
1.3 Post-Translational Modifications of pRB  
As described in the above mentioned sections, pRB plays host to numerous functions that 
comprise the roles of pRB as a prototypical tumour suppressor. To understand the various 
contrasting functions and interactions, it is necessary to further study the post-
translational modifications of pRB to offer potential insights into the control of these 
different functions. 
1.3.1 CDK Phosphorylation of pRB  
As mentioned in previous sections, pRB has been observed to be phosphorylated by 
Cyclin/CDK complexes upon mitogen stimulation. The initial characterization of CDK 
phosphorylation of pRB was based on altered electrophoretic migration throughout the 
cell cycle with the observation of two unique species of pRB with regards to 
electrophoretic migration(Buchkovich et al., 1989). Through various biochemical and 
mass spectrometry methods, 15 CDK sites have been identified on pRB (Fig 1.4)(Brown 
et al., 1999; Connell-Crowley et al., 1997; Dephoure et al., 2008; Zarkowska and 
Mittnacht, 1997). In early G1 of cycling cells or G0 in non-cycling cells, few of these 
CDK sites are phosphorylated (Ezhevsky et al., 2001; Ezhevsky et al., 1997). This  
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Figure 1.4: CDK Phosphorylation Sites and Lysine Acetylation Sites on pRB 
pRB is extensively phosphorylated on CDK sites dispersed throughout the pRB primary 
structure with 15 known CDK phosphorylation sites confirmed through various 
biochemical and mass spectrometry means. Acetylation is found on both K873 and K874 
in the C-terminus of pRB and is highlighted in purple. Acetylation has also been 
demonstrated on other residues of pRB, indicated in orange, though these are primarily 
only validated using mass spectrometry methods.  
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species of lightly phosphorylated pRB has been termed the hypo-phosphorylated form of 
pRB which is able to retain binding to E2Fs. These early phosphorylation events are 
catalyzed by activation of Cyclin D-CDK4/6 complexes which interact through a docking 
site in the C-terminus of pRB (Ezhevsky et al., 2001; Wallace and Ball, 2004). Following 
these initial phosphorylation events, as the cell progresses towards S phase of the cell 
cycle, activation of Cyclin E-CDK2 complexes leads to substantially more 
phosphorylation of pRB(Harbour et al., 1999b). This species of substantially 
phosphorylated pRB is characterized as the hyper-phosphorylated form of pRB and is 
unable to bind E2Fs through the general interaction, though retaining specific E2F1 
binding as mentioned previously. This body of highlighted work suggests two basic 
structural conformations of pRB, that of the hypo-phosphorylated form and a 
conformation for the hyper-phosphorylated form of pRB. This potentially simplistic view 
of two pRB phosphorylated forms of functional consequence though has begun to be 
challenged through the emergence of recent works which suggest this is an 
oversimplification of pRB regulation by CDK phosphorylation. Highlighted below are 
works first suggesting that specific CDK phosphorylation sites on pRB may in fact have 
unique functional consequences in respect to pRB function and that the 
hypophosphorylated form of pRB which has previously described as the active form of 
pRB may in fact be attributed to a collection of mono-phosphorylated pRB isomers. 
 As pointed out above, pRB contains 15 CDK sites, and while initial work has 
focused on the hypo and hyper-phosphorylated forms of pRB, data has begun to emerge 
in regards to potential roles of single phosphorylation sites in regards to specific 
regulation of pRB function. Initial work to characterize phosphorylation sites suggested 
that the C-terminal phosphorylation sites were sufficient to disrupt pRB from E2Fs with 
more recent x-ray crystallography studies of pRB C-terminus with E2F1/DP1 peptides 
demonstrating a similar phenomenon(Chow et al., 1996; Knudsen and Wang, 1996; 
Rubin et al., 2005). Similar studies though for the N-terminus of pRB suggest that CDK 
sites in this region are also sufficient to disrupt pRB binding to E2Fs. A crystallography 
study using the pRB N-terminus with the small pocket suggests that T373 
phosphorylation leads to folding of the N-terminus into the small pocket in an allosteric 
manner which may block both E2F and LXCXE cleft mediated interactions with 
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pRB(Burke et al., 2012). Furthermore, phosphorylation sites in the linker region of the 
small pocket have also been examined with interesting results. S612 has been suggested 
to be phosphorylated in scenarios of DNA damage, and although this site has been 
implicated as a CDK phosphorylation site, under this cellular context phosphorylation is 
catalyzed by Chk1/2 and leads to retention of E2F1 binding(Inoue et al., 2007; 
Zarkowska and Mittnacht, 1997). S608 which also lies in the linker region, using a 
phospho-mimetic and crystallography was observed to disrupt binding of E2Fs to pRB 
highlighting that two proximal phosphorylation sites may in fact have highly divergent 
functional roles(Burke et al., 2012).   
 More recently, insights into pRB phosphorylation by CDKs have begun to emerge 
that further gives credence to the idea that control and regulation of single 
phosphorylation sites may control the regulation of different discrete pRB functions.  
Through analysis using 2D gel electrophoresis, Narasimha and colleagues demonstrate 
that in the G1 phase of the cell cycle, pRB persists in distinct isomers of the mono-
phosphorylated form with 14 distinct mono-phosphorylated pRB isomers present 
(Narasimha et al., 2014). It was noted that upon DNA damage, pRB remained in a mono-
phosphorylated form which was mediated by CyclinD/CDK4/6 activity(Narasimha et al., 
2014). Finally the authors noted that upon terminal differentiation of myoblasts into 
myotubules, pRB was uniquely present in an un-phosphorylated form(Narasimha et al., 
2014).  
 From the above highlighted works, a more elaborate model of pRB 
phosphorylation begins to be elucidated wherein the simple model of hypo and hyper-
phosphorylated pRB can be expanded to envision a system of multiple simultaneously 
existing species containing different arrangements of site specific phosphorylation. This 
potential model though begins to ask the question of how this tightly regulated system of 
distinct single phosphorylation population of unique pRB molecules is maintained in 
such a manner. To answer this potential question requires a full understanding of 
regulation of not only pRB phosphorylation but of pRB dephosphorylation which will be 
discussed in more breadth below. 
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1.3.2 Acetylation of pRB  
pRB has been shown to be acetylated at K873/K874 in the C-terminus when bound by 
the p300/CBP co-activator complex(Chan et al., 2001b). Acetylation of these two lysine 
residues, which reside in a CDK docking site in the C-terminus of pRB, leads to a 
reduction in pRB phosphorylation by CDKs(Chan and La Thangue, 2001; Lowe et al., 
2002; Wallace and Ball, 2004). Furthermore, acetylation of these two residues of pRB 
occurs in the cellular context of DNA damage and this leads to the accumulation of 
pRB/E2F1 complexes (Markham et al., 2006). These results suggest that pRB acetylation 
at these two sites may be beneficial in contexts of cellular arrest. This idea is further 
substantiated with the observations that pRB acetylation occurs in the cellular context of 
differentiation. With the use of C2C12 myoblasts, it was observed that pCAF, the 
p300/CBP associated factor, is recruited to pRB to acetylate K873/K874 and that this is 
required for transactivation of MyoD and proper differentiation (Nguyen et al., 2004). 
Similar effects were also observed for keratinocyte differentiation, with acetylation 
defective mutants unable to promote differentiation but were able to arrest cells in a 
SaOS2 arrest assay (Pickard et al., 2010).   
 The observations recognized previously though in the literature could in fact be 
attributed to other acetylation sites on pRB, due to the lack of commercial site specific 
antibodies available for acetyl K873/K874 pRB. Mass spectrometry and global 
proteomics approaches have elucidated other less characterized acetylation sites on pRB 
which could be responsible for the mechanistic observations which have been ascribed to 
K873/K874 acetylation. A study by Choudhary and colleagues (Choudhary et al., 2009) 
treated A549, Jurkat and MV4-11 human cell lines with HDAC inhibitors and performed 
mass spectrometry analysis on lysates from these cells. From this study, the authors 
determined that K427, K548, K640, K652, and K896 on pRB were found to be acetylated 
in this context of HDAC inhibitor treated cells. Similar proteomic scale studies have 
identified K925 in the C-terminus as being acetylated, again with human cell lines that 
had been treated with HDAC inhibitors (Hornbeck et al., 2012). Less characterized 
acetylation sites within pRB are highlighted in Figure 1.4, where we can observe sites of 
acetylation throughout pRB. Interestingly, similar proteomic approaches were performed 
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in hepatocellular carcinoma tissue isolated from patients and strikingly from this study, 
only acetylation on K874 could be detected on pRB from these patient samples (Zhao et 
al., 2010). These findings offer insights that acetylation of pRB may be sensitive to 
context and cell type. The findings that K874 acetylation was present through mass 
spectrometry of Hepatocellular carcinoma tissue samples without K873 acetylation, in 
contrast to previous reports, highlights the potential for both acetyl K873/K874 to not be 
present in combination. 
 These results suggest that pRB acetylation may play a role in regulating the 
phosphorylation of pRB in contexts where stable cell cycle arrest is required such as in 
the scenarios of DNA damage or in differentiation. The work highlighted above though 
asks the general question of whether this is a widespread occurrence or limited to very 
specialized scenarios. Furthermore, most work was performed under in vitro conditions 
and thus does pRB acetylation play a functional consequence under physiological 
conditions remains to be answered. 
1.4 pRB Dephosphorylation  
As discussed in section 1.3.1 detailing pRB phosphorylation by CDKs, an emerging 
picture of highly regulated site specific phosphorylation is beginning to emerge with the 
potential for each individual phosphorylation site regulating specific functions and 
interactions of pRB. While the heavily studied role of pRB phosphorylation offers some 
insights into this regulation, the much less characterized area of pRB dephosphorylation 
offers an enticing means of regulating and controlling the distribution of specific pRB 
mono-phosphorylated isomers that have been shown to exist.  
1.4.1 Regulation of pRB Dephosphorylation in the Cell Cycle 
In a normal cycling cell, pRB becomes hyper-phosphorylated in late G1 and exists in this 
species until late in mitosis. In the transition between metaphase and anaphase, there is a 
sharp decrease in the activity of CDKs that result from the degradation of cyclin B by the 
anaphase-promoting complex (APC) (King et al., 1995). At this point, pRB is actively 
dephosphorylated primarily by the enzyme complex of Protein Phosphatase 1 (PP1) 
(Alberts et al., 1993; Ludlow et al., 1993). Evidence also exists that Protein Phosphatase 
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2 A (PP2A) may also play a role in mitotic dephosphorylation of pRB(Alberts et al., 
1993). The end result of this targeted dephosphorylation of pRB is a re-establishment of a 
large population of hypo-phosphorylated pRB which can then re-engage and repress 
E2Fs (Fig 1.5). 
 From this work, pRB was determined to be actively dephosphorylated in anaphase 
by primarily PP1 but many questions remain in regards to how this process is specifically 
regulated. Both PP1 and PP2A typically reside in multimeric complexes and interestingly 
multiple different regulatory subunits for both enzymes have been shown to physically 
interact with pRB(Ceulemans and Bollen, 2004; Kolupaeva and Janssens, 2012).  
1.4.2 Regulation of pRB Dephosphorylation in Conditions of 
Cellular Stress 
As shown above, pRB dephosphorylation is a tightly regulated and coordinated event in a 
normal cell cycle context. Outside of this tightly ordered system of regulation, pRB can 
also be actively dephosphorylated in cellular contexts of stress such as oxidative stress, 
DNA damage and hypoxia. Once again, PP1 has been shown to play a major role in the 
dephosphorylation of pRB in response to cell cycle arrests induced by DNA damage or 
hypoxia (Dou and Lui, 1995; Krucher et al., 2006; Lentine et al., 2012). Upon DNA 
damage PP1 is activated to promote the dephosphorylation of pRB to a hypo-
phosphorylated state that can maintain the interaction with E2Fs and block their 
transcriptional activity to mediate an acute arrest of the cell cycle. (Wang et al., 2001) In 
addition protein phosphatase 2 also interacts with and dephosphorylates pRB in some 
cellular contexts(Kolupaeva and Janssens, 2012). Thus the current understanding of pRB 
dephosphorylation in response to cellular stresses illuminates the potential complexity of 
regulating the various phosphorylation sites of pRB.  
1.4.3 A Specific and Direct Interaction of PP1 with the C-Terminus 
of pRB 
As mentioned above, pRB dephosphorylation appears to be a tightly regulated cellular 
program involving multiple different multimeric protein complexes. Previous studies 
carried out by our lab in coordination with another group determined that the C-terminus 
17 
 
  
Figure 1.5: pRB Functions Throughout the Cell Cycle 
As more research emerges on pRB, a broader understanding is beginning to emerge of 
pRB function outside of the G1-S transition of the cell cycle. As highlighted previously 
in Fig 1.2, pRB has historically been considered to mediate the G1-S transition of the cell 
cycle by controlling E2F target gene transcription. Emerging work also indicates the 
pRB/E2F1 complexes persist beyond G1 of the cell cycle through the „Specific‟ 
interaction. A pRB LXCXE interaction with the Condensin II complex also persists 
beyond G1 of the cell cycle and mediates chromosomal condensation of pericentromeres 
at major satellite repeats. CKI- Cyclin Dependent Kinase Inhibitors.  
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of pRB contains a unique site that allows for direct interaction between PP1 and 
pRB(Hirschi et al., 2010). Analysis of a crystal structure of the pRB870-882 C-terminus 
peptide bound to the α isoform of the PP1 catalytic subunit indicates that pRB binding is 
outside of the catalytic cleft of PP1. Furthermore, binding of pRB to PP1 occurs in a 
similar manner and location to that of the interactions that commonly occur between PP1 
targeting subunits and PP1, with the interactions being mediated by a “RVxF” motif. This 
binding interaction and motif interestingly is not present in the other pocket protein 
family members, p107 and p130, indicating that this is a unique mechanism of regulation 
for pRB. 
 Intriguingly, the minimal binding domain of PP1 to pRB directly overlaps a 
previously identified binding site for Cyclin-CDK complexes in the C-terminus, and that 
binding of each of these complexes was competitive and mutually exclusive(Hirschi et 
al.). Furthermore, maximal catalytic activity from both Cyclin-CDK and PP1 complexes 
towards a pRB substrate were achieved when bound to the docking site in the C-
terminus. As mentioned above, pRB is able to be acetylated at K873/K874, and previous 
works suggest that acetylation at these sites is responsible for decreased CDK activity in 
regards to a pRB substrate. Potentially acetylation at these sites may regulate binding and 
access to the docking site, further adding a potential layer of regulation and complexity to 
this mechanism. 
1.5 Hypothesis and Objectives  
As described above in the preceding sections of this chapter, while a large body of work 
has been established on general regulation of pRB phosphorylation, little has been 
explored in the regulation of pRB dephosphorylation and functional consequences of 
selective phosphorylation of pRB in regards to CDK phosphorylation.  I hypothesize that 
the regulation of pRB dephosphorylation is critical in regulating pRB function and 
activity. Furthermore, I hypothesize that acetylation of lysines 873 and 874 in the pRB C-
terminus potentially could play a role in the regulation of pRB dephosphorylation. To set 
up about trying to answer these questions regarding the regulation of pRB 
dephosphorylation I have outlined two specific aims in this thesis to address this 
question.  
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 In the first aim, I detail work on generating and characterizing an antibody that 
recognizes pRB acetylation in the C-terminus on lysines 873 & 874 which sit directly 
within previously known CDK and PP1 binding sites within pRB. I validated this 
antibody and demonstrated that this antibody specifically recognized acetylation of 
lysines 873/874 of pRB using in vitro acetylation assays. Using this antibody, I examined 
the ability of pRB to be properly phosphorylated by CDK2. I then examined cellular 
conditions suggested from previous works on pRB acetylation to enrich for this 
modification and found no evidence using my antibody of the presence of acetyl-
K873/K874 pRB under these outlined cellular conditions. 
 In the second aim, I present work to create a novel gene targeted mouse model of 
pRB which is defective for binding of PP1 to the pRB C-terminus. This mouse model, 
which I classify as the Rb1ΔPP1, would allow for a proper and discrete study of pRB 
dephosphorylation by PP1 and the potential mechanistic insights of this unique 
interaction with pRB. Through the attempt to generate this mouse model of pRb, I was 
unable to obtain viable mESCs which contained our targeted allele.  
 The results I present in this thesis detail the generation and characterization of an 
anti-acetyl pRB antibody and demonstrate limited functional impact of this specific post-
translational modification. Furthermore, I have outlined the attempt to generate a mouse 
model for pRB which is deficient for dephosphorylation and have observed that this 
model was unable to be created through conventional gene targeting approaches.  
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Chapter 2  
2 Methods 
2.1 Plasmids 
All plasmids used in this thesis are described in Table 2.1. psCodon1-GST-RBLP has 
been previously reported (Cecchini and Dick, 2011). pBSKRB12KBSacI was a kind gift 
from Jean Wang and has been previously been reported (Chau et al., 2002) 
2.2 Plasmid Construction 
2.2.1 psCodon1-GST-RBLP-K873/K874A  
PCR conditions and primers discussed here are detailed in 2.3.2 and Table 2.2. pFAD228 
plasmid was used as a PCR template for RB379 and FD155 primers. This PCR product 
was isolated and digested with BamH1/EcoR1. This digested product was then ligated 
into psCodon1-GST-pRB LP which had been digested with BamH1/EcoRI. This lead to 
the insertion of a fragment of pRB containing K873/K874A mutations into a bacterial 
GST expression vector.  
2.2.2 pRBΔPP1 Targeting Vector Construction 
 A targeting vector was constructed that allows for introduction of the pRBΔPP1 
mutation (R869F F870R) in exon 25 of the mouse Rb1 gene. A brief outline of the 
targeting vector construction is detailed in Figure 2.1 and an overview of how the 
construct facilitates recombination is provided in Figure 4.2. Our strategy for targeting 
was adopted from a previously published method targeting a nearby region (Chau et al., 
2002). The pFAD326 Plasmid was constructed by Michael Thawites contained R869F 
F870R mutations in Exon 25 along with an insertion of an EcoRI restriction enzyme site 
in intron 24. A PGK-Neo cassette flanked by LoxP sites was inserted at a BglII site in 
intron 25. The pBSKΔBH plasmid was created by Fred Dick with a bluescript vector   
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Table 2.1 Description of Plasmids Used and Created 
Plasmid 
Name 
Genes 
encoded 
Expression 
Obtained/ 
Constructed 
Resistance 
Stock 
Number 
psCodon1-
GST-RBLP 
GST, pRBLP Bacterial Fred Dick Ampicillin 0526 
pRB-
DeltaPP1 
Targeting 
Vector 
Rb1 N/A Paul Stafford* Ampicillin 0683 
pFAD326  Bacterial 
Michael 
Thawites 
Ampicillin 0684 
pBSKRB12k
bSacI 
 Bacterial Jean Wang Ampicillin 0685 
pBSKΔBH  Bacterial Fred Dick Ampicillin 0686 
pBSK-
PGKNeoLox
2 
Neomycin Bacterial Fred Dick 
Ampicillin, 
Neomycin 
0137 
pCRII-
Rb1ex24 
Rb1 Bacterial Fred Dick 
Ampicillin, 
Kanamycin 
0523 
pFAD228 
pRB 
K873/K874A 
Mammalian Fred Dick Ampicillin 0220 
psCodon1-
GST-RBLP-
K873/K874A 
pRB 
K873/K874A 
Bacterial Paul Stafford* Ampicillin 0687 
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(pBSK) modified to remove the BamHI and HindIII sites from the multiple cloning site. 
A vector containing a 20 kb fragment of the 3‟ end of the Rb1 gene (pBSK-RB12kbSacI) 
was digested with SacI to obtain a 12 kb fragment, which was then ligated into the 
pBSKΔBH plasmid after a SacI digest, to make the pFAD321 plasmid. The 326 plasmid 
and pFAD321 plasmids were then digested with BamHI/HindIII, and ligated together to 
make the final targeting construct. The targeting construct was then maxi-prepped, and 
sequenced to confirm exon and neo cassette sequences and restriction mapped to confirm 
correct assembly. 
2.3 PCR and Primers  
2.3.1 PCR Conditions to Create GST-RB LP K873/K874A (GST 
Expression) 
Master Mix per Reaction: 
 9 µL  H2O 
 1 µL Vent Polymerase Buffer 
 1 µL 2 mM dNTPs 
 1 µL 100 mM FD 155 Primer 
 1 µL 100 mM  Rb379 Primer 
 1 µL Vent Polymerase 
 2 µL  200 ng/µL pFAD228 
PCR Reaction Conditions: 
1. 94°C 2 mins 
2. 94°C 30 secs 
3. 45°C 30 secs 
4. 72°C 2 mins 30 secs 
5. Go to Step #2, 34 times 
6. 72°C 10 mins 
7. 4°C Indefinite 
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Figure 2.1: Schematic of the Rb1ΔPP1 Targeting Construct 
Schematic detailing the construction of the Rb1
ΔPP1 
targeting construct. pBSK-
Rb12kbSacI was cut with SacI restriction enzyme and ligated into pBSKΔBH, a 
bluescript plasmid which had BamHI and HindIII sites in the multiple cloning site 
removed. This plasmid, pFAD321 was cut with BamHI and HindIII along with pFAD326 
and were ligated together to create the Rb1
ΔPP1 
targeting construct. B-BamHI, H-HindIII, 
R-EcoRI, S-SacI,  25*-Exon 25 with ΔPP1 mutation, 25- Exon 25, 26-Exon 26, 27- Exon 
27 
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Table 2.2: List of Primers 
Primer 
Name 
Oligonucleotide sequence Obtained/Constructed 
Rb379 
GCGGGATCCGAAGAGGTGAATGTAATTC
CTCC 
Fred Dick 
FD155 CGCGAATTCCTCATTTCTCTTCCTTGTTTG Fred Dick 
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2.4 Antibody Generation and Purification 
Antibody generation and purification was performed as previously described(Taya et al., 
2003). Synthetic peptides were generated against amino acids of the C-terminus of 
human pRB through Covance Discovery and Translational Services Inc. These peptides 
were 15 mer sequences (Residues 867-881) that flanked residues K873/K874 and were 
either unmodified or synthesized with acetylation of K873/K874. Two rabbits were 
immunized with the acetylated peptide following a standard 118 day protocol. The 
animals were subjected to a 3 week cycle of antigen boosts and test bleeds were taken 10 
days following the boosts. Serum from initial test bleeds was used for initial ELISA 
screening to determine the specificity of the serum towards the modified epitope. Serum 
was then purified for anti-acetyl K873/K874 pRB antibody in 5 mL batches using a two-
step immunoaffinity column chromatography procedure. Acetyl K873/K874 pRB and 
unmodified K873/K874 immunoaffinity columns were prepared using a NPPKPL-Ac-K-
Ac-K-LRFDIEG peptide sequence used to immunize the rabbits along with an 
unmodified NPPKPL-K-KLRFDIEG. Peptides were reduced by incubation with an 
immobilized TCEP reducing gel (5 mL for 2.5 mg of peptide, Pierce) for 15 minutes at 
room temperature in gravity flow columns (Biorad). Reduced peptides were eluted in 0.5 
mL fractions and the fractions containing the highest peptide concentrations, as 
determined by Bradford assay, were pooled and coupled to 4 mL each of Sulfolink 
Coupling gel (Pierce). Non-specific binding sites on the gel were blocked with 50 mL L-
cysteine HCL and washed with 1M NaCl.  
 Antibody purification then was carried out, first by clearing the serum of debris 
by centrifugation at 4°C at 1660 × g for 10 minutes. The cleared serum was then passed 
through the immunoaffinity column coupled with modified acetyl-K873/K874 pRB 
peptide at 4°C with flow through being saved. The column was then washed with 25 mL 
of 1X PBS at 4°C. Bound IgG then was eluted from the column through a two-step 
process. Initially, 8 mL of 0.2M Glycine-HCl pH 2.5 was added to the column and 1 mL 
fractions were collected in microfuge tubes containing 95µL of 1.5M Tris-HCl pH 8.8 to 
immediately neutralize each fraction to ~ pH 7.3. Following this the second elution step 
was carried out where 8 mL of 0.2M Glycine-HCl pH 1.9 was added to the column and 1 
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mL fractions were collected into tubes containing 160µL of 1.5M Tris-HCl pH 8.8 to 
immediately neutralize each fraction to ~ pH 7.3. To remove non-acetyl-K873/K873 pRB 
antibodies, elution fractions containing IgG as determined by Bradford assay were loaded 
into the column coupled with unmodified peptide. This column was then subjected to a 
similar approach as described above for the modified column, wherein the flow through 
from the PBS wash step was isolated. Following purification, both columns were washed 
with 25 mL of 1X PBS at 4°C, then washed with 10 mL of 1X PBS with 0.05% Sodium 
azide at 4°C and stored for future use at 4°C. Purified acetyl-K873/K874 pRB antibody 
was dialyzed against 2L of 1xPBS and diluted with storage buffer (1xPBS, 20% 
Glycerol, 0.05% Sodium azide and 100 µg/mL BSA), and aliquoted and stored at -20°C. 
2.5 Enzyme Linked Immunosorbent Assay 
ELISA was adapted from a previously described method for testing antibody 
specificity(Taya et al., 2003). ELISA screening was performed to test the specificity of 
acetyl-K873/K874 antibody toward acetyl K873/K874 pRB substrate. Synthetic peptides 
from Covance Discovery and Translational Services generated for acetyl-lysine 873/874 
and non-acetylated pRB were used in this subsequent assay. 0.3 µg of peptides (or TBS 
in the negative control) were added in triplicate to the wells of a flat bottom 96 well plate 
(Falcon). The plate was incubated for 5 hours at room temperature to adsorb the peptides 
to the bottom of the wells after which the supernatant was removed and 50 µL of 
Blocking buffer (1x PBS, 3% BSA) was added for 2 hours at room temperature. Wells 
were washed 3 times in TBST after which 30 µL of a titration (1/10, 1/100, 1/1000, 
1/10000, 1/100000, 1/1000000, 1/100000000 in blocking buffer) of either serum or 
purified anti-acetyl K873/K874 antibody was added to the wells and incubated for 1 hour 
at room temperature. Wells were then washed 5 times in TBST after which 30 µL of 
1:10000 diluted goat-anti rabbit secondary antibody coupled to alkaline phosphatase 
(Sigma) in blocking buffer was added to the wells for 1 hour at room temperature. The 
plate was then washed 3 times with TBST, followed by the addition of 50 µL of Akaline 
Phosphatase Yellow (para-Nitrophenylphosphate) Liquid Substrate system for ELISA 
(Sigma). Colorimetric analysis was then performed by reading absorbance at 405 nm on 
Wallac-Victor plate reader. 
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2.6 Peptide SPOT Membrane Assay 
Peptide arrays of the pRB C-terminal region for both mouse and human consisting of 122 
and 123 15-mer peptides each consisting of a one amino acid overlap were synthesized in 
the Li lab as spots on a nitrocellulose membrane (Reineke and Sabat, 2009). Peptide 
sequences for both the mouse and human arrays are outlined in Table 2.3. To carry out 
epitope characterization of the indicated pRB antibodies, the membrane was rehydrated 
in 100% ethanol for 1 minute, then distilled water was added to 50% and the membrane 
was incubated at room temperature for 15 minutes. The membrane then was washed in 
distilled water 3 times for 15 minutes each followed by 3 washes with Tris buffered 
saline-0.1% Tween20 (TBST- 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween20) for 10 
minutes each. The membrane was then blocked for 3 hours at room temperature by 
incubation in 5% non-fat milk TBST. The membrane was then washed 3 times for 10 
minutes each in TBST and incubated with the indicated primary antibody. pRB rabbit 
polyclonal M153 antibody (Santa Cruz) was diluted 1:500, pRB mouse hybridoma 
monoclonal antibody RB4.1 was diluted 1:10 from culture supernatant, pRB rabbit 
antibody generated in our lab against the final 15 amino acids of the human pRB 
sequence C15 was diluted 1:500 and pRB Sheep antibody M136 generated in our lab 
against the mouse C-terminus was diluted 1:500. All primary antibodies used were 
diluted in 5% non-fat milk TBST. Following primary antibody treatment, the membrane 
was blocked for 3 hours at room temperature with 5% non-fat milk TBST. The 
membrane was then washed 3 times for 10 minutes with TBST and incubated with 
peroxidase secondary antibody (anti-mouse for RB4.1, anti-rabbit for Santa Cruz M153 
and C15, and anti-sheep for M136) at a 1:10000 dilution in 5% non-fat milk TBST. The 
membrane was then washed 3 times for 10 minutes in TBST and developed using 
chemiluminescence detection solution (0.1M Tris pH 8.5, 390 µM courmaric acid, 2.46 
mM luminol, 0.02% H2O2) and exposure to Amersham hyperfilm (GE Healthcare). 
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Table 2.3: List of Human and Mouse pRB Peptides for SPOT Array 
Peptide # Human Peptide Mouse Peptide 
1. FPSSPLRIPGGNIYI SSSPLRIPGGNIYIS 
2. PSSPLRIPGGNIYIS SSPLRIPGGNIYISP 
3. SSPLRIPGGNIYISP SPLRIPGGNIYISPL 
4. SPLRIPGGNIYISPL PLRIPGGNIYISPLK 
5. PLRIPGGNIYISPLK LRIPGGNIYISPLKS 
6 LRIPGGNIYISPLKS RIPGGNIYISPLKSP 
7. RIPGGNIYISPLKSP IPGGNIYISPLKSPY 
8. IPGGNIYISPLKSPY PGGNIYISPLKSPYK 
9. PGGNIYISPLKSPYK GGNIYISPLKSPYKI 
10. GGNIYISPLKSPYKI GNIYISPLKSPYKIS 
11. GNIYISPLKSPYKIS NIYISPLKSPYKISE 
12. NIYISPLKSPYKISE IYISPLKSPYKISEG 
13. IYISPLKSPYKISEG YISPLKSPYKISEGL 
14. YISPLKSPYKISEGL ISPLKSPYKISEGLP 
15. ISPLKSPYKISEGLP SPLKSPYKISEGLPT 
16. SPLKSPYKISEGLPT PLKSPYKISEGLPTP 
17. PLKSPYKISEGLPTP LKSPYKISEGLPTPT 
18. LKSPYKISEGLPTPT KSPYKISEGLPTPTK 
19. KSPYKISEGLPTPTK SPYKISEGLPTPTKM 
20. SPYKISEGLPTPTKM PYKISEGLPTPTKMT 
21. PYKISEGLPTPTKMT YKISEGLPTPTKMTP 
22. YKISEGLPTPTKMTP KISEGLPTPTKMTPR 
23. KISEGLPTPTKMTPR ISEGLPTPTKMTPRS 
24. ISEGLPTPTKMTPRS SEGLPTPTKMTPRSR 
25. SEGLPTPTKMTPRSR EGLPTPTKMTPRSRI 
26. EGLPTPTKMTPRSRI GLPTPTKMTPRSRIL 
27. GLPTPTKMTPRSRIL LPTPTKMTPRSRILV 
28. LPTPTKMTPRSRILV PTPTKMTPRSRILVS 
29. PTPTKMTPRSRILVS TPTKMTPRSRILVSI 
30. TPTKMTPRSRILVSI PTKMTPRSRILVSIG 
31. PTKMTPRSRILVSIG TKMTPRSRILVSIGE 
32. TKMTPRSRILVSIGE KMTPRSRILVSIGES 
33. KMTPRSRILVSIGES MTPRSRILVSIGESF 
34. MTPRSRILVSIGESF TPRSRILVSIGESFG 
35. TPRSRILVSIGESFG PRSRILVSIGESFGT 
36. PRSRILVSIGESFGT RSRILVSIGESFGTS 
37. RSRILVSIGESFGTS SRILVSIGESFGTSE 
38. SRILVSIGESFGTSE RILVSIGESFGTSEK 
39. RILVSIGESFGTSEK ILVSIGESFGTSEKF 
40. ILVSIGESFGTSEKF LVSIGESFGTSEKFQ 
41. LVSIGESFGTSEKFQ VSIGESFGTSEKFQK 
42. VSIGESFGTSEKFQK SIGESFGTSEKFQKI 
43. SIGESFGTSEKFQKI IGESFGTSEKFQKIN 
44. IGESFGTSEKFQKIN GESFGTSEKFQKINQ 
45. GESFGTSEKFQKINQ ESFGTSEKFQKINQM 
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Peptide # Human Peptide Mouse Peptide 
46. ESFGTSEKFQKINQM SFGTSEKFQKINQMV 
47. SFGTSEKFQKINQMV FGTSEKFQKINQMVS 
48. FGTSEKFQKINQMVS GTSEKFQKINQMVSN 
49. GTSEKFQKINQMVSN TSEKFQKINQMVSNS 
50. TSEKFQKINQMVSNS SEKFQKINQMVSNSD 
51. SEKFQKINQMVSNSD EKFQKINQMVSNSDR 
52. EKFQKINQMVSNSDR KFQKINQMVSNSDRV 
53. KFQKINQMVSNSDRV FQKINQMVSNSDRVL 
54. FQKINQMVSNSDRVL QKINQMVSNSDRVLK 
55. QKINQMVSNSDRVLK KINQMVSNSDRVLKR 
56. KINQMVSNSDRVLKR INQMVSNSDRVLKRS 
57. INQMVSNSDRVLKRS NQMVSNSDRVLKRSA 
58. NQMVSNSDRVLKRSA QMVSNSDRVLKRSAE 
59. QMVSNSDRVLKRSAE MVSNSDRVLKRSAEG 
60. MVSNSDRVLKRSAEG VSNSDRVLKRSAEGG 
61. VSNSDRVLKRSAEGS SNSDRVLKRSAEGGN 
62. SNSDRVLKRSAEGSN NSDRVLKRSAEGGNP 
63. NSDRVLKRSAEGSNP SDRVLKRSAEGGNPP 
64. SDRVLKRSAEGSNPP DRVLKRSAEGGNPPK 
65. DRVLKRSAEGSNPPK RVLKRSAEGGNPPKP 
66. RVLKRSAEGSNPPKP VLKRSAEGGNPPKPL 
67. VLKRSAEGSNPPKPL LKRSAEGGNPPKPLK 
68. LKRSAEGSNPPKPLK KRSAEGGNPPKPLKK 
69. KRSAEGSNPPKPLKK RSAEGGNPPKPLKKL 
70. RSAEGSNPPKPLKKL SAEGGNPPKPLKKLR 
71. SAEGSNPPKPLKKLR AEGGNPPKPLKKLRF 
72. AEGSNPPKPLKKLRF EGGNPPKPLKKLRFD 
73. EGSNPPKPLKKLRFD GGNPPKPLKKLRFDI 
74. GSNPPKPLKKLRFDI GNPPKPLKKLRFDIE 
75. SNPPKPLKKLRFDIE NPPKPLKKLRFDIEG 
76. NPPKPLKKLRFDIEG PPKPLKKLRFDIEGA 
77. PPKPLKKLRFDIEGS PKPLKKLRFDIEGAD 
78. PKPLKKLRFDIEGSD KPLKKLRFDIEGADE 
79. KPLKKLRFDIEGSDE PLKKLRFDIEGADEA 
80. PLKKLRFDIEGSDEA LKKLRFDIEGADEAD 
81. LKKLRFDIEGSDEAD KKLRFDIEGADEADG 
82. KKLRFDIEGSDEADG KLRFDIEGADEADGS 
83. KLRFDIEGSDEADGS LRFDIEGADEADGSK 
84. LRFDIEGSDEADGSK RFDIEGADEADGSKH 
85. RFDIEGSDEADGSKH FDIEGADEADGSKHL 
86. FDIEGSDEADGSKHL DIEGADEADGSKHLP 
87. DIEGSDEADGSKHLP IEGADEADGSKHLPA 
88. IEGSDEADGSKHLPG EGADEADGSKHLPAE 
89. EGSDEADGSKHLPGE GADEADGSKHLPAES 
90. GSDEADGSKHLPGES ADEADGSKHLPAESK 
91. SDEADGSKHLPGESK DEADGSKHLPAESKF 
92. DEADGSKHLPGESKF EADGSKHLPAESKFQ 
93. EADGSKHLPGESKFQ ADGSKHLPAESKFQQ 
94. ADGSKHLPGESKFQQ DGSKHLPAESKFQQK 
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Peptide # Human Peptide Mouse Peptide 
95. DGSKHLPGESKFQQK GSKHLPAESKFQQKL 
96. GSKHLPGESKFQQKL SKHLPAESKFQQKLA 
97. SKHLPGESKFQQKLA KHLPAESKFQQKLAE 
98. KHLPGESKFQQKLAE HLPAESKFQQKLAEM 
99. HLPGESKFQQKLAEM LPAESKFQQKLAEMT 
100. LPGESKFQQKLAEMT PAESKFQQKLAEMTS 
101. PGESKFQQKLAEMTS AESKFQQKLAEMTST 
102. GESKFQQKLAEMTST ESKFQQKLAEMTSTR 
103. ESKFQQKLAEMTSTR SKFQQKLAEMTSTRT 
104. SKFQQKLAEMTSTRT KFQQKLAEMTSTRTR 
105. KFQQKLAEMTSTRTR FQQKLAEMTSTRTRM 
106. FQQKLAEMTSTRTRM QQKLAEMTSTRTRMQ 
107. QQKLAEMTSTRTRMQ QKLAEMTSTRTRMQK 
108. QKLAEMTSTRTRMQK KLAEMTSTRTRMQKQ 
109. KLAEMTSTRTRMQKQ LAEMTSTRTRMQKQR 
110. LAEMTSTRTRMQKQK AEMTSTRTRMQKQRM 
111. AEMTSTRTRMQKQKM EMTSTRTRMQKQRMN 
112. EMTSTRTRMQKQKMN MTSTRTRMQKQRMNE 
113. MTSTRTRMQKQKMND TSTRTRMQKQRMNES 
114. TSTRTRMQKQKMNDS STRTRMQKQRMNESK 
115. STRTRMQKQKMNDSM TRTRMQKQRMNESKD 
116. TRTRMQKQKMNDSMD RTRMQKQRMNESKDV 
117. RTRMQKQKMNDSMDT TRMQKQRMNESKDVS 
118. TRMQKQKMNDSMDTS RMQKQRMNESKDVSN 
119. RMQKQKMNDSMDTSN MQKQRMNESKDVSNK 
120. MQKQKMNDSMDTSNK QKQRMNESKDVSNKE 
121. QKQKMNDSMDTSNKE KQRMNESKDVSNKEE 
122. KQKMNDSMDTSNKEE QRMNESKDVSNKEEK 
123. QKMNDSMDTSNKEEK  
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2.7 Cell Culture 
C33A human cervical carcinoma cells were obtained from the American Type Culture 
Collection (ATCC). Cells were thawed from stocks stored at -150°C and plated onto 
10cm plates cultured in Dulbecco‟s Modified Eagle Medium (DMEM) supplemented 
with penicillin (100U/mL), L-glutamate (2 mM), streptomycin (50 µg/mL) and 10% fetal 
bovine serum (FBS). Cells were grown in a humidified incubator at 37°C with 5% CO2. 
2.8 Recombinant Protein Purification 
Recombinant GST Protein purification was performed as previously described(Cecchini 
and Dick, 2011). Recombinant Proteins used for downstream applications were generated 
using the following protocol. Plasmids encoding the desired recombinant protein were 
transformed into competent BL21 Gold E.coli cells and plated onto 10 cm dishes 
containing LB growth media with agar and supplemented with ampicillin (100 µg/mL) 
and incubated for 16hrs at 37°C. Single colonies were isolated and grown in 25 mL of LB 
media supplemented with 100 µg/mL ampicillin and grown for 16 hrs at 37°C shaking at 
200 RPM in a C-24 New Brunswick Orbital Shaker. Cultures were transferred to 1 L of 
LB media supplemented with 100 µg/mL ampicillin and grown for 4hrs at 25°C shaking 
at 200 RPM. Cultures were then induced with 100 µM IPTG and were transferred to a 
16°C incubator and left shaking at 200 RPM for 16 hrs in a G-25 New Brunswick Shaker. 
Cell cultures were then centrifuged at 1660 × g for 45 min at 4°C to pellet cells. Cell 
pellets were then either stored at -80°C or purification was performed immediately. 
 Cell pellets (either fresh or frozen) were washed with 1X Phosphate Buffererd 
Saline (PBS) and then suspended in GST Lysis Buffer (20 mM Tris pH 7.5, 0.5 M NaCl, 
0.5 mM EDTA, 10% Glycerol, 0.5% NP-40, 20 mM DTT and 0.25 mM PMSF). 
Suspended cell pellets were subsequently sonicated at amplitude 3 with a 20 sec pulse 3 
times. Cellular debris was then pelleted by centrifugation at 1660 × g for 30 mins at 4°C 
and supernatant was isolated. The supernatant was then combined with 50% slurry of 
glutathione-sepharose beads (GE healthcare) and then rocked for 1hr at 4°C. Glutathione 
beads were subsequently centrifuged at 106 × g, 4°C for 2 mins with the resulting 
supernatant removed and then washed 3 times with High Salt GST Lysis Buffer ( 20 mM 
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Tris pH 7.5, 1 M NaCl, 0.5 mM EDTA, 10% Glycerol, 1% NP-40, 20 mM DTT and 0.25 
mM PMSF). The beads were then washed 5 times with lysis buffer and finally washed 
once with KCL Buffer (20 mM Tris pH 7.5, 0.1 M KCl, 10% Glycerol, 0.02% NP-40, 20 
mM DTT and 0.25 mM PMSF. GST tagged recombinant proteins were then eluted from 
Glutathione beads with  the addition of 500 µL of GST Elution Buffer (50 mM Tris pH 
8.0, 0.1M KCl, 0.1 mM EDTA, 10% Glycerol, 0.02% NP-40, 20 mM DTT, 0.25 mM 
PMSF and 200 mM Glutathione) for 1 hr rocking at 4°C. Beads were then centrifuged at 
106 × g for 5 mins at 4°C and supernatant was dialyzed against 1000x excess KCL buffer 
at 4°C for 16 hrs. Protein samples were then aliquoted, snap frozen and stored at -80°C 
until required for use. 
2.9 GST Pulldown Binding Experiments 
Recombinantly produced proteins were used for these assays and this procedure is 
detailed above in 2.8. This procedure was carried out as previously reported (Dick et al., 
2000). In general 20 µL of Glutathione-sepharose beads were washed with 400 µL of 
Low Salt GSE Buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 1 mM DTT and 0.1% NP-40) twice before being centrifuged at 106 × g, 4°C 
3mins. The beads were then suspended in 400 µL Low Salt GSE Buffer and 200 µg of 
cell extract was added along with 3 µg of the desired GST tagged recombinant protein. 
This mix was then rocked for 1 hr at 4°C and subsequently washed with twice with Low 
Salt GSE Buffer. Beads were then resuspended 100 µL of 1X SDS-PAGE sample Buffer 
(62.5 mM Tris pH 6.8, 10% Glycerol, 2% SDS, 72.5 mM β-ME and Bromophenol Blue) 
and boiled for 5 mins at 95°C. Beads subsequently were centrifuged at 20800 × g for 1 
min and supernatant was loaded on SDS-PAGE gel of indicated percentage for optimal 
resolution for Western blotting and GST protein loading quantification.  
2.10 Western Blotting and Immunoprecipitations 
 Western Blotting was used to determine protein abundance in samples and has 
been previously described (Cecchini and Dick, 2011). In general, protein samples were 
electrophoresed on 8% polyacrylamide gels unless otherwise stated. Gels were run in 1X 
SDS-PAGE running buffer (25 µM Tris Base, 200 µM Glycine and 0.1% SDS) at 150-
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200 volts using a Biorad PowerPac HC 250 V to achieve proper resolution of desired 
protein targets. Proteins were then transferred onto a nitrocellulose membrane (GE 
Amersham Hybrid ECL) for 1hr on ice at 100 V in 1X Western Blot transfer buffer (48 
µM Tris Base, 368 µM Glycine, 0.1% SDS and 20% Methanol). Membranes were then 
blocked in 1X TBST (20mM Tris pH7.5, 150 mM NaCl and 0.1% Tween-20) with 3% 
skim milk powder for 1hr rocking at room temperature. Membranes were then treated 
with primary antibody solution in 1x TBST with 3% skim milk powder at indicated 
working dilutions described below, overnight rocking at 4°C. Membranes were 
subsequently washed 3 times for 10 mins with 1X TBST and then treated with secondary 
antibodies of indicated species conjugated to HRP diluted 1:2000 in 1X TBST with 3% 
skim milk. Membranes were left shaking for 1hr at 25°C before being washed 3 times for 
10 mins with 1X TBST. Membranes were incubated with ECL solution (Supersignal 
West Dura Extended Duration Substrate, Thermo Scientific) sufficient to properly cover 
membrane for 2 mins. Membranes were then developed using ChemiDoc apparatus 
(BioRad) with ImageLab software (BioRad) to achieve proper exposure for indicated 
proteins.  
2.11 In Vitro Acetylation Assay 
GST-pRBLP recombinant proteins were used for this assay and were produced as 
described above in 2.8. This method was adapted from previously reported methods 
(Avvakumov et al., 2003; Kuninger et al., 2007). 3.5 µg of recombinant protein were 
added to Acetylation Buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% 
NP-40, 1 mM PMSF, 1 mM DTT), with 10 µM of acetyl-CoA and the volumes were 
made up to 20 µL with Acetylation buffer. Indicated reactions were then supplied 1 µg of 
recombinant pCAF HAT domain (Cayman Chemicals) to act as the acetyltransferase. 
Acetylation reactions were carried out for 10 mins at 30°C on a rotating platform. 
Following this, samples were snap frozen to be used in downstream assays or the 
reactions were stopped with the addition of SDS-PAGE sample buffer and 
electrophoresed on 8% polyacrylamide gels.  
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Table 2.4: Description of Antibodies 
Antibody 
Name 
Epitope Species Supplier / Source Application 
RB4.1 pRB Mouse Hybridoma WB, IP 
M153 pRB Rabbit Santa Cruz (sc-7905) WB, IP 
Ac-pRB 
K873/K874 
ac-pRB 
Rabbit Paul Stafford* WB, IP 
4G12 Ac-Lysine Mouse Millipore WB 
M136 pRB Sheep Dick Lab/Michael Thwaites IP 
07-631 CDK2 Rabbit Upstate IP 
C15 pRB Rabbit Dick Lab WB 
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2.12 In Vitro Kinase Assay 
The CDK2 in vitro kinase assay was carried out according to a previously described 
method (Forristal et al., 2014). Nuclear extracts from proliferating C33A cells were 
collected as described above. 100 µg of extract was then added to 50 µL of Protein G 
dynabeads pre-bound with 4 µg of rabbit IgG or 4 µg of α-CDK2 for 1.5 hrs at 4°C. The 
beads were then washed twice in Kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2 and 1 
mM DTT). Washed beads were subsequently resuspended in 30 µL of Kinase buffer, 1 
µL of γ-ATP32 (10 µCi), 2 µg of recombinant GST-pRBLP and the volume was made up 
to50 µL with Kinase buffer. The kinase reaction was carried out for 20 mins at 30°C and 
then stopped with the addition of 5x Laemmli SDS Page Buffer. Samples were then 
electrophoresed on 8% polyacrylamide gels and stained with Coomassie brilliant blue 
solution to resolve protein bands. The gels were then dried and imaged to allow for 
comparison of protein loading. The gel was then exposed to Amersham Hyperfilm MP 
(GE healthcare) for proper resolution of radiolabelled substrates and autoradiography was 
performed.  
2.13 Immunopurified-Kinase Assay 
Recombinant GST-pRB LP was prepared as discussed above in 2.8. Acetylated GST-
pRB LP was prepared as described in 2.11. CDK2 was immunoprecipitated from 
proliferating C33A cells using 4 µg of α-CDK2 antibody (Upstate) or rabbit IgG that had 
been prebound by rocking with protein G dynabeads (Invitrogen) at 4°C for 1 hour. 6 µg 
of acetyl-K873/K874 antibody and M136 antibody which had been purified against the 
unmodified peptide discussed in 2.11, were prebound to protein G dynabeads for 1 hour 
rocking at 4°C. 5.5 µg of either modified or unmodified GST-pRB LP protein or GST 
was added to each IP for 1 hour rocking at 4°C.  Each set of IPs was washed twice with 
Kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2 and 1 mM DTT). CDK2 IP beads 
were resuspended in 30 µL of Kinase buffer and combined with acetyl K873/K874 pRB 
or unmodified pRB IP beads which had been resuspended with 30 µL of Kinase buffer, 
with 12 µL added to the kinase reaction. 1 µL of γ-ATP32 (10 µCi) was added to each 
reaction and the final volume was brought up to 50 µL with the addition of Kinase buffer. 
Kinase reactions were then carried out as described in 2.9. 12 µL of each IP acetyl-
49 
 
K873/K874 pRB or unmodified pRB IP was set aside for Western blot analysis as 
described above. 
2.14 mESC Cell Culture  
Cell culture for mESCs was performed to standard protocols as previously described 
(Sicinski et al., 1995). mESCs were cultured in DMEM media with 4500 mg/L Glucose,  
2 mM glutamine, 0.1 mM Non-Essential amino acids (Gibco #11140-050), 0.1 mM β-
mercaptoethanol (Sigma M7522) diluted in PBS, Leukemia Inhibitory Factor (LIF, 
Millipore, ESG1106) 10
5
 Units/L media, 50 µg/mL G418 (Sigma SLBB2604) and 15% 
Fetal Bovine Serum (FBS).  mESCs were cultured on plates coated with 0.1% gelatin 
solution (Swine skin type II, Sigma G2500) with mitomycin c treated MEFs which were 
plated the night before and left at 37°C to adhere to the gelatin coated plate. The mESCs 
were grown in a humidified incubator at 37°C with 5% CO2 and sub-cultured until 
optimal density was reached on a 10 cm dish. Cells were trypsinized with 0.25% 
Trypsin/0.04% EDTA (GIBCO) with media being changed 1 hour prior to treatment with 
trypsin.  
2.15 Southern Blot Screening  
The targeting construct was linearized by a NotI digestion, and provided to the London 
Regional Transgenic and Gene Targeting facility where mouse embryonic stem cells 
(mESCs) were electroporated and grown in neomycin selection medium. Southern blot 
screening of mESCs was carried out as previously reported (Cecchini et al., 2014; Isaac 
et al., 2006). Electroporated mESCs were selected and underwent clonal expansion onto 
24 well culture plates. Cells were lysed in Tail Lysis Buffer (50 mM Tris pH 8.0, 100 
mM NaCl, 0.1% SDS, 0.1 mM EDTA) with 200 µg/µL of Prot K overnight at 37°C. 
Genomic DNA was then isolated through phenol chloroform extraction and quantified 
using a nanodrop. 10 µg of DNA was digested overnight at 37°C with 20 units of the 
desired restriction enzyme. The next morning, restriction digests were spiked with 20 
units of restriction enzyme and left to digest at 37°C for 8 hours. Digested genomic DNA 
was then electrophoresed in a 0.8% agarose gel without Ethidium bromide (EtBr) 
overnight at 20V. The agarose gel was then stained in a TAE (40 mM Tris acetate, 1mM 
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EDTA, pH 8.2) with Ethidium Bromide and visualized to determine migration distances 
of the ladder and presence of digested DNA in the lanes. The gel was then washed 2 
times for 30 minutes each shaking at room temperature in Wash Buffer 1 (1.5M NaCl, 
0.5M NaOH). Following this the gel was washed for 5 minutes in Milli-Q water and then 
the gel was washed 2 times for 30 minutes each shaking at room temperature in Wash 
Buffer 2 (1 M Ammonium acetate, 20 mM NaOH). The gel was then placed in a 
Stratagene Posiblot apparatus and the transfer was carried out overnight at room 
temperature onto a nitrocellulose membrane (GE NitroPure 45 micron nitrocellulose 
membrane). The membrane was then dried at room temperature for 1 hour and then 
baked at 80°C for 1 hour.  The membrane was then rehydrated with Hybridization Buffer 
(0.2% SDS, 25 mM Na3PO4, 0.1% Sodium pyrophosphate, 4 mM EDTA, 8 mM Tris 
Base, 600 mM NaCl, 0.2% Ficoll 400, 0.2% polyvinylpyrrolidone , 0.2% Bovine serum 
albumin), placed in a glass cylinder and rotated at 65°C for 2 hours. During this time, the 
indicated probe was labelled and quantified as discussed below in 2.15.1. The 
hybridization buffer then was changed and fresh buffer was added with 1,000,000 CPM 
of 
32
P-α dCTP labelled probe per mL of hybridization buffer. The membrane was left to 
incubate with probe while rotating overnight at 65°C. The next day the membrane was 
washed 3 times for 10 minutes at room temperature with Low Stringency Buffer (0.1% 
SDS, 300 mM NaCl, 30 mM Sodium Citrate pH 7.0). The membrane then was washed 3 
times for 10 minutes each at 65°C with High Stringency Buffer (0.1% SDS, 30 mM 
NaCl, 3 mM Sodium Citrate pH 7.0). The membrane then was exposed to Amersham 
hyperfilm (GE Healthcare) for autoradiography.  
2.15.1 Southern Blot: Labeling and Purifying the Probe 
Reactions are scaled for 25 ng of extracted probe DNA but can be scaled up as needed. 
Labeling Reaction: Using Agilent Prime-It II Random Primer Labeling Kit (Agilent, 
300385) contents 
25 ng of DNA 
10 µL Random Primers 
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Add H2O up to 34 µL 
5 min @ 95°C 
Then Add: 
10 µL 5x dCTP buffer 
5 µL of 
32
P-α dCTP 
1 µL Klenow 
  Place in 37°C water bath for 30 mins 
Purifying the Probe:  
Fill a 3 mL syringe with glass wool to 1 mL mark, being careful not to tightly pack the 
wool 
Add Sephadex G-50 Beads suspended in TE buffer to the top of the glass wool to 1.5 mL 
mark, making sure beads are even over the wool 
Centrifuged column at 210 × g for 1 minute and check levels and quality of sephadex 
layer. Add more and centrifuge as needed. 
Add labeled probe to column with 100 µL volume max/column, centrifuge (210 × g, 1 
min) syringe in a conical tube and collect flow through which is labeled probe. 
Add 10 µg sheared of salmon sperm DNA per 100 µL of flow through 
Heat for 5 mins at 95°C, quantify activity of the probe by liquid scintillation.  
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Chapter 3  
3 Study of pRB K873/K874 Acetylation 
3.1 Analysis of pRB Antibody Specificity in the pRB C-
Terminus 
To study post-translational modifications of the pRB C-terminus, a comprehensive 
understanding of epitope locations for antibodies that will be used for Western blotting 
and immunoprecipitations (IPs) is critical for interpreting these results. As mentioned 
above in the introduction, a specific portion of the pRB C-terminus is of interest to my 
research due to the presence of the PP1 and CDK docking site, and the presence of the 
K873/K874 residues that have been demonstrated to be acetylated. To study this region 
of pRB, we mapped epitopes for the antibodies that we commonly use. The antibodies 
that I examined for analysis were the following; mouse monoclonal hybridoma RB4.1, 
rabbit polyclonal pRB antibody M153 from Santa Cruz, pRB rabbit antibody C15 
generated in our lab against the final 15 amino acids of the human pRB C-terminus and a 
sheep pRB antibody M136 generated against the 136 amino acids of the mouse pRB C-
terminus.  
 To map epitopes of the various pRB antibodies available, I performed a peptide 
SPOT assay. This consisted of an array of 122 or 123 peptides of the mouse and human 
pRB C-terminal regions respectively. Each peptide is 15 amino acids long and each had a 
one amino acid difference from its neighbour providing full coverage of all the 15 amino 
acid peptides possible from the C-terminus of pRB. With these peptides spanning the 
entire C-terminus, I incubated the membrane with each of the indicated antibodies and 
visualized the membranes using standard western blotting procedures. From this analysis 
for each respective antibody, specific epitopes or regions of preferred binding were 
observed for each antibody. For RB4.1, I observed from the spot pattern depicted in Fig 
3.1A that the epitope for this antibody corresponds to amino acids 822-836 in the human 
sequence and 815-830 in the mouse sequence, which is illustrated in Fig 3.2A. For the 
pRB C15 antibody, I observed from the peptide array in Fig 3.1B that binding could be 
attributed to the C-terminus encompassing amino acids 908 to 928 in the human 
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sequence. It was also observed that it was bound to one mouse peptide as shown in Fig. 
3.1B, with this peptide corresponding to amino acids 906-920 in the mouse pRB C-
terminus. Presented in Fig 3.2B is a schematic detailing C15 binding to human pRB C-
terminus corresponding to residues 908-928 and binding in the mouse pRB C-terminus, 
corresponding to residues 906-920. Both polyclonal antibodies exhibited widespread 
binding throughout the C-terminus but did have regions of preference. From analysis of 
the array presented in Fig 3.1C for M153, we observed peptides that were recognized 
specifically. Detailed in Fig 3.2C in a diagram of the pRB C-terminus is the regions of 
binding I observed for M153. While it is important to note that binding was observed in 
regions encompassing the PP1-CDK docking sites as well as acetylation sites 
K873/K874, many other prominent epitopes existed in the C-terminus including strong 
epitopes in the early C-terminus. Through analysis of the array presented in Fig 3.1D for 
M136, we again observed that there was a wide swath of binding throughout the C-
terminus of pRB with epitopes encompassing the PP1-CDK docking site and K873/K874 
acetylation sites. The epitopes for M136 were more concentrated on this region and 
displayed minimal binding to the early portion of the pRB C-terminus.  
3.2 Generation and Characterization of Anti-Acetyl 
K873/K874 pRB Antibodies 
As described in my introduction, the pRB protein has been shown to be acetylated in the 
C-terminus on lysine residues 873 and 874 (Chan et al., 2001). This acetylation has been 
shown to occur within a region of pRB that contains binding motifs for Cyclin-CDK 
complexes as well as PP1 (Hirschi et al., 2010), thus the potential exists that these 
modifications may act in a regulatory manner to control CDK phosphorylation or PP1 
dephosphorylation of pRB. Though these post-translational modifications of pRB present 
a unique and exciting means of regulation of pRB, no commercially available antibodies 
exist for any combination of K873/K874 acetylation. Therefore, to further characterize 
pRB K873/K874 acetylation and the potential regulatory nature of these post-
translational modifications, we set out to create an antibody that was specific for these   
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Figure 3.1: Characterization of pRB Antibodies 
A) Peptide spot membrane of human and mouse pRB assayed for mouse derived 
monoclonal antibody RB4.1 epitopes. Peptides which demonstrated reactivity are 
indicated by their peptide number. B) Peptide spot membrane of human and mouse pRB 
probed with a rabbit antibody generated in our lab against the 15 C-terminal amino acids 
of human pRB. C) Peptide spot membrane of human and mouse pRB for rabbit derived 
polyclonal antibody M153 from Santa Cruz. D) Peptide spot membrane of human and 
mouse pRB probed with a goat antibody generated in our lab against the C-terminal 136 
amino acids of mouse pRB. N=1 for all peptide arrays 
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Figure 3.2: Schematic of pRB Antibody Epitopes on Human and Mouse pRB 
A) Schematic detailing the regions in the pRB C-terminus that demonstrated epitopes for 
mouse hybridoma antibody RB4.1. B) Schematic detailing the epitope in the pRB human 
C-terminus for rabbit pRB antibody C15. C) Schematic detailing the epitopes in the pRB 
C-terminus for rabbit polyclonal antibody M153 from Santa Cruz. D) Schematic 
detailing the epitopes in the pRB C-terminus for sheep polyclonal antibody M136 
developed in the Dick Lab 
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modifications. This process is outlined in the illustration presented in Figure 3.3A.  
Covance Research Products Inc. was contracted to make an antibody that was able to 
specifically detect acetyl-K873/K874. Two rabbits were immunized with a 15 amino acid 
acetylated peptide that surrounded K873/K874 (NPPKPL-Ac-K-Ac-K-LRFDIEG) 
following a standard 118 day protocol. The animals were subjected to a 3 week cycle of 
antigen boosts and test bleeds were taken 10 days following the boosts. From the initial 
test bleeds, Enzyme linked immunosorbent assays (ELISA) was carried out to test serum 
for antibody production and response against both a synthetically modified peptide versus 
an unmodified peptide, which are depicted in Figure 3.3B. Presented in Figure 3.4A is 
quantification of these experiments, where we can see that serum was able to elicit a 
significant response against both acetylated and unmodified peptide when compared to 
the negative control through the use of statistical analysis at the half maximal absorbance 
dilution. Through statistical analysis, no significant difference was observed for the 
unmodified versus the acetylated peptide. With this result, this encouraged us to continue 
production of serum and to begin purification and characterization of the antibody. For 
purification of acetyl K873/K874 pRB antibodies we used a two-step protocol of 
immunoaffinity column chromatography. Serum was first passed through a column that 
contained acetyl K873/K874 coupled peptides and I eluted under low pH conditions to 
isolate antibodies. To eliminate antibodies that detected non-acetylated or pRB, the 
elution was passed through a second column that contained unmodified coupled peptide 
(NPPKPL-K-K-LRFDIEG) and unbound flow through was collected for downstream use. 
An ELISA was then carried out to test specificity of purified antibodies towards 
acetylated peptide versus unmodified peptide. From this analysis, presented in Figure 
3.4B, the purified antibody was able to recognize the acetylated peptide with at least 100 
times higher affinity when compared to the unmodified peptide. Statistical analysis using 
a T-test confirmed that this difference was significant. This result suggested to us that the 
purified antibody was responsive to our antigen with a high order of specificity and 
prompted us to further examine and characterize this antibody in regards to detection of 
pRB K873/K874 acetylation.  
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Figure 3.3: Generation of an Antibody Against Acetylated pRB 
A) Schematic diagram for the generation and purification of anti-acetyl K873/K874 pRB 
antibodies. Serum was also used for indicated experiments where purification steps were 
bypassed. B) Schematic of the two synthetic peptides used for antibody generation and 
purification with mouse pRB sequence and residue numbers indicated. Synthetic 
acetylation's on residues K873/K874 are indicated in purple. Residues highlighted in blue 
are critical in the Protein phosphatase 1 docking site of pRB. 
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Figure 3.4: ELISA Analysis Demonstrating Specificity of Anti-Acetyl K873/K874 
pRB Antibody 
ELISA experiments were carried out to analyze specificity of anti-acetyl K873/K874 
pRB antibodies. Experiments were performed in triplicate on the same plate. A) Serum 
was diluted and added to wells coated with the indicated peptides. Following addition of 
Alkaline phosphatase secondary antibody and substrate, absorbance values were plotted 
against serum dilution for each respective peptide or negative control. ** P<0.05 for 
acetyl and wt peptides to negative control at half maximal absorbance dilution using a T-
test. B) Antibodies against acetyl K873/K873 pRB were and added to wells coated with 
the indicated peptide or TBS as a negative control. Absorbance was determined for each 
peptide and plotted against the indicated dilution. * P<0.05 for acetyl versus wt peptide at 
half maximal absorbance dilution using a T-test. Error bars were plotted as standard 
deviations. 
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3.3 Acetyl K873/K874 pRB Antibody Specifically 
Detects Acetylated Recombinant pRB 
Our initial characterization of the acetyl K873/K874 pRB antibody suggested specificity 
towards acetylated peptide when compared to unmodified peptide, we next wanted to 
examine more stringent conditions to further asses the specificity of our antibody. I set 
out to carry out in vitro acetylation assays and assess specificity by the use of western 
blotting. To begin these characterizations, I first set up in vitro acetylation assays using 
recombinant GST-pRB LP as substrate of the Histone Acetyl Transferase (HAT) domain 
of pCAF, which has been characterized in the past to acetylate pRB(Pickard et al., 2010). 
These assays were carried out with either recombinant GST-pRB LP or non-specific 
substrates GST or BSA. From the western blot presented in Figure 3.5A, we can see that 
when probed with acetyl K873/K874 pRB antibody, we see a strong signal for acetylated 
GST-pRB LP compared to GST-pRB LP lacking pCAF enzyme, as well as GST or BSA. 
When this blot was probed with an acetyl-Lysine antibody as observed in Figure 3.5B, 
we can see a specific signal for GST-pRB LP in the presence of pCAF. From these 
observations, we suggest that our acetyl K873/K874 pRB antibody is able to specifically 
recognize acetylated GST-pRB LP using in vitro acetylation. To further test the 
specificity of our acetyl K873/K874 pRB antibody, specifically towards acetylation of 
residues K873/K874 versus other potential acetylation sites on pRB a mutant of pRB was 
tested in which K873 and K874 were changed to alanine. When in vitro acetylation 
assays were carried out over a time course using this mutant of GST-pRB LP as shown in 
Figure 3.6, and then probed with acetyl-K873/K874 pRB antibody, we observed that 
wildtype GST-pRB LP shows a specific signal when compared to both unmodified 
wildtype GST-pRB LP as well as GST-pRB LP K873/K874A. When probed with an 
acetyl-lysine antibody, no discernible signal could be observed for any of the reaction 
conditions. Furthermore, when a Coomassie loading control was examined for the 
indicated reactions, it was observed that similar loading was achieved for the three 
different GST-pRB LP reaction groups, and although no signal was seen with the acetyl-
lysine antibody western blot, the positive signal seen from the acetyl K873/K874 pRB 
blot suggests that the experimental conditions were successful. Thus it can be concluded 
that pRB acetylation on K873/K874 can be specifically detected by our acetyl- 
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purified K873/K874 acetylated GST-pRB LP and unmodified GST-pRB LP. From 
observation of Fig. 3.9A, we noticed that the acetylated K873/K874 GST-pRB LP that 
was immunopurified exhibited less incorporation of γ-32P-ATP compared to unmodified 
wildtype GST-pRB LP. When densitometry was performed on the autoradiogram, I  
Figure 3.5: Anti-Acetyl-pRB Antibody Specifically Detects Modified GST-pRB LP 
3 µg of recombinant GST-pRB LP (aa 379-928) was used as a substrate in an in vitro 
acetylation assay with recombinant pCAF. BSA and GST were used as non-specific 
substrates and reactions without pCAF were used to gauge specificity towards modified 
substrate. Following 30 min of incubation at 37°C, samples were analyzed by SDS-
PAGE and western blotting. A) Blots as probed with anti-acetyl K873/K874 pRB 
antibody while in panel B), samples were probed with an acetyl-lysine antibody. N=1 for 
both blots. N=1 for both blots presented in this figure.  
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Figure 3.6: Anti-Acetyl K873/K874 pRB Antibody Specifically Detects Modified 
GST-pRB LP 
3 µg of recombinant GST-pRB LP or K873/K874A GST-pRB LP were used for in vitro 
acetylation by recombinant pCAF. GST was used as non-specific substrate and reactions 
without pCAF were used to gauge specificity of antibodies towards modified substrate. 
Samples were incubated for the above indicated times and then subjected to analysis by 
SDS-PAGE and western blotting. The top image is of a western blot using anti-acetyl 
K873/K874 pRB antibody, with the lower image showing Coomassie staining of GST-
pRB LP protein loading for each respective sample. The middle image is a western blot 
using anti-acetyl-lysine-antibody. Bands indicated with an * correspond to GST-pRB LP. 
N=1 for both blots and Coomassie gel presented in this figure.  
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K873/K874 antibody and that this antibody demonstrates sufficient specificity with 
regards to the in vitro assays carried out to undertake further analysis of pRB acetylation 
using this reagent. 
3.4 CDK Phosphorylation of pRB May Be Affected by 
pRB K873/K874 Acetylation 
To further characterize pRB acetylation on lysine residues 873 and 874, I set out to 
examine CDK kinase activity towards pRB which had been acetylated on these residues 
through in vitro assays. Previous work suggests that acetylation of pRB at these residues 
disrupts CDK phosphorylation of pRB, though many of these studies are based on 
molecular modeling of the pRB C-terminus using X-ray crystallography structures (Chan 
et al., 2001; Lowe et al., 2002; Wallace and Ball, 2004). Thus to assess CDK 
phosphorylation of pRB, I carried out an in vitro kinase assay using CDK2. CDK2 was 
immunoprecipitated from proliferating C33A cells, which are pRB null, and thus will not 
offer endogenous pRB to confound our interpretation. Recombinant GST-pRB LP that 
was either modified through the use of an in vitro acetylation assay or unmodified acted 
as substrate for immunoprecipitated CDK2. As presented in Figure 3.7, we can see that 
the ability of pRB to act as a CDK2 substrate seemed to be unaffected by the presence of 
K873/K874 acetylation compared to unmodified pRB when compared to levels of 
recombinant GST-pRB LP present in each lane. From these observations, we questioned 
whether the population of GST-pRB LP that was acetylated was substantial enough to 
mask the effects of non-acetylated pRB, due to the high sensitivity of detection of 
radiolabelled substrate. With this possible caveat, I then set out to further test this using a 
more selective approach. To carry out this more selective approach, I established an 
immune-purification approach for isolating K873/K874 acetylated GST-pRB LP from the 
population, the outline for this experiment is detailed in Figure 3.8. For this protocol, I 
used either the K873/K873 acetyl pRB antibody or M136 antibody, which had been 
purified against the unmodified peptide of the K873/K874 antibody. This allowed for us 
to normalize for epitope efficiency in regards to immunoprecipitation between the two 
respective antibodies. Following immunoprecipitation of the indicated substrates, CDK2 
kinase assays were performed to compare the incorporation of γ-32P-ATP between 
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observed that the band intensity for incorporation of γ-32P-ATP for the unmodified GST- 
purified K873/K874 acetylated GST-pRB LP and unmodified GST-pRB LP. From 
observation of Fig. 3.9A, we noticed that the acetylated K873/K874 GST-pRB LP that 
was immunopurified exhibited less incorporation of γ-32P-ATP compared to unmodified 
wildtype GST-pRB LP. When densitometry was performed on the autoradiogram, I 
observed that the band intensity for incorporation of γ-32P-ATP for the unmodified GST-
pRB LP was reduced compared to the acetylated GST-pRB LP. When the loading of the 
samples was analyzed using Western blot analysis with the RB4.1 antibody, we can see 
from Fig. 3.9B that both antibodies were able to pull down similar levels of either acetyl 
K873/K874 pRB or unmodified pRB, suggesting the differences in CDK2 
phosphorylation we observed could be attributed to the acetylation of K873 and K874. 
From these experiments, we have evidence to suggest that acetylation of these two 
indicated lysine residues in pRB may in fact regulate the ability of pRB to serve as a 
CDK2 substrate in vitro. 
3.5 Acetylation of pRB at K873 and K874 is Unable to 
be Detected In Vivo  
The in vitro results presented earlier in this chapter suggested that the antibody that we 
had developed for acetyl K873/K874 pRB was a highly specific reagent that could be 
used to examine the occurrence of these post-translational modifications in cells. To 
determine whether pRB could be acetylated on K873/K874 in cells that were 
asynchronously proliferating, I carried out immunoprecipitations for pRB from two 
different cell types and performed western blot analysis on IP fractions using acetyl 
K873/K874 pRB antibody. As demonstrated in Figure 3.10B, when probed with our 
antibody we were unable to detect the presence of acetyl K873/K874 pRB. This is in 
accordance with Western blot analysis presented in Figure 3.10A, which demonstrated 
the IP efficiency for pRB. Furthermore both blots were run with a positive standard, 
which was GST-pRB LP which had been acetylated using an in vitro acetylation assay. 
The positive signal from this standard as shown in Figure 3.10B demonstrates that our 
antibody was able to detect modified pRB, suggesting no technical reasons for the lack of 
bands corresponding to acetyl K873/K874 in the IP lanes.  
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Figure 3.7: CDK Phosphorylation of Acetylated GST-pRB LP 
Kinase activity of CDK2 was determined against acetylated and unmodified GST-pRB 
LP substrates as described in the previous figure. 3 µg of GST-pRB LP substrates were 
exposed to immunoprecipitated CDK2 along with γ-
32
P-ATP at 30°C for 20 mins. 
Samples were then resolved on a polyacrylamide gel. Phosphate incorporation was 
determined by autoradiography and relative protein levels are shown by Coomassie 
staining. N=1 for the autoradiograph and Coomassie for those presented in this figure. 
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Figure 3.8: Schematic of Immunopurified Acetyl K873/K874-pRB Substrate Kinase 
Assay 
Procedure used to immunopurifiy GST-pRB LP substrate that had undergone acetylation 
and its use as a substrate in a CDK2 kinase assay 
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Figure 3.9: Acetylation of pRB Inhibits CDK Phosphorylation 
A) Kinase activity of CDK2 was determined against acetylated and unmodified GST-
pRB LP substrates as described in the previous figure. Substrates were exposed to 
immunoprecipitated CDK2 along with γ-
32
P-ATP at 30°C for 20 minutes. Samples were 
then resolved by SDS-PAGE, a representative radiogram is shown with densitometric 
quantification below. B) Immunoprecipitation efficiency of acetylated and unmodified 
GST-pRB LP substrates by their respective antibodies was determined by Western 
blotting. Equal volumes were analyzed by SDS-PAGE followed by Western pRB with an 
independent antibody. N=1 for experimental data presented in this figure.  
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From these results, we next wanted to examine conditions from the literature that have 
been suggested to increase the accumulation of acetyl K873/K874 pRB. One of the 
conditions that have been suggested from prior work is double stranded DNA breaks 
induced by etoposide treatment (Carnevale et al., 2012; Markham et al., 2006). To 
examine DNA damage induced pRB acetylation of K873/K874, I treated ML1 cells 
with100 µM of Etoposide for 8 hours and performed GST-E7 pulldowns to enrich for 
pRB from these cells. Following GST-E7 pulldowns, Western blot analysis on the 
pulldown fractions of Etoposide treated and DMSO treated cells was performed and 
presented in Figure 3.11A. We observed that treatment of ML1 cells with Etoposide lead 
to an activation of p53 signaling as demonstrated by increased pS15-p53, and thus an 
activation of DNA damage signaling. From Western blot analysis presented in Figure 
3.11B, we can observe that GST-E7 pulldown from these cells was sufficiently able to 
enrich for endogenous pRB. When pulldown fractions were then probed with the acetyl 
K873/K874 pRB antibody, we observed no detectable signal from either the input or 
pulldown fractions, suggesting that acetyl K873/K874 pRB was in fact not present as 
shown in Figure 3.11C. Further, through Western blot analysis using an acetyl-lysine 
antibody as depicted in Figure 3.11D, we observed a band in the input fraction that could 
correspond to pRB but this band was not replicated in the pulldown fraction, suggesting 
this band does not correspond to acetyl-pRB and agrees with the results demonstrated in 
Figure 3.11C. From these experiments, we can suggest that acetyl K873/K874 pRB is not 
enriched for in cells that have undergone DNA double strand breaks. 
 Based on previous work in our lab, it has been suggested that upon DNA double 
strand breaks induced by Etoposide, pRB and E2F1 complexes are formed that include 
acetylated pRB. I treated U2OS cells with 100 µM Etoposide for 8 hours and performed 
an immunoprecipitation for E2F1. Presented in top portion of Figure 3.12 is Western blot 
analysis for E2F1 demonstrating that the IP was successful while in the bottom portion of 
Figure 3.12 is Western blot analysis using acetyl K873/K874 pRB antibody. From this 
analysis, we can see that there is no significant enrichment of acetyl K873/K874 signal 
over IgG in either treatment group. This result suggests that under a scenario of DNA 
damage, acetyl K873/K874 pRB is not associating with a pRB bound E2F1 population.  
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  Figure 3.10: Unable to Detect Ac-pRB in Asynchronous Cells 
U2OS and HEK293 nuclear extract was harvested from asynchronous proliferating cells. 
Immunoprecipitations were performed for pRB with 2 mg of extract from both sets and 
corresponding samples were resolved by SDS-PAGE with indicated western blots 
performed. 200 µg of nuclear extract was taken and loaded as input while 300 ng of Ac-
GST-pRB LP was used as a positive control. A) A western blot against pRB using an 
antibody independent of the immunoprecipitation. B) Western blot with acetyl 
K873/K874 pRB antibody. N =1 for the blots presented in this figure. 
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Figure 3.11: Unable to Detect Ac-K873/K874 pRB Following DNA Damage 
GST pulldown binding experiment using recombinant GST-E7 with 2 mg of nuclear 
extract from ML1 cells treated with either 100 µM Etoposide (Etop) for 8 hrs or DMSO 
vehicle as control. 200 µg of nuclear extract from either DMSO or Etop were used as the 
corresponding input. A) Western blot for pS15 -p53 to demonstrate that Etoposide 
treatment lead to an increase in DNA damage signaling. Bands indicated with the * 
correspond to pS15 p53. B) Western blot for pRB to demonstrate that the recombinant 
GST-E7 was able to successfully pulldown pRB from these cells and to demonstrate 
similar loading between treatment groups. C) Western blot for ac K873/K874-pRB using 
purified antibody from both treatment groups. D) Western Blot for acetyl lysine from 
both treatment groups. N =1 for all the blots presented in this figure.  
72 
 
 
 
  
Figure 3.12: Unable to Detect Ac-K873/K874 pRB Binding to E2F1 
E2F1 immunoprecipitations were performed from U2OS cells treated with 100 µM 
etoposide for 8 hrs or DMSO vehicle control. 2 mg of nuclear extract were collected 
from each treatment group with 200 µg of extract used for input. A) Western blot for 
E2F1 confirming immunoprecipitation from both treatment groups. B) Western blot for 
ac-K873/K874-pRB is performed on each immunoprecipitated fraction using purified 
antibody. N= 1 for both blots presented in this figure.  
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Chapter 4  
4 The Rb1ΔPP1 Mouse 
4.1 Generation of Rb1ΔPP1 Gene Targeted Mouse 
Model 
Previous work in our lab has identified a specific mutation in the pRB C-terminus, 
identified as R876F/ F877R, which is able to disrupt Protein Phosphatase 1 binding while 
retaining CDK2 binding in the analogous region (Hirschi et al., 2010). This mutation 
allows for the study of PP1 binding in the pRB C-terminus and its direct function in 
regards to pRB while still maintaining proper CDK phosphorylation of pRB. To study 
this potential means of phosphorylation regulation of pRB, I set out to create a gene 
targeted mouse which incorporated the analogous mouse mutation R869F/F870R into the 
mouse Rb1 gene and we designate this allele of Rb1 the Rb1
ΔPP1
 mutation. As presented 
in the schematic in Figure 4.1B, this mutation in the Rb1 allele would potentially allow 
for a mutant of pRb that would discretely disrupt PP1 mediated activation of pRB while 
maintaining CDK phosphorylation. This theoretically could alter the equilibrium between 
these states and force pRb towards a more hyperphosphorylated form in this gene 
targeted mouse model. 
 To generate this mouse model for Rb1
ΔPP1
, detailed in Figure 4.1A is a schematic 
detailing the work flow associated with generating this mouse model. The first step was 
the creation of the targeting vector to allow for homologous recombination of our desired 
mutation into the mouse Rb1 locus. We used a previous method to target a nearby region 
in Rb1 as a basis for our strategy, which is summarized in Figure 4.2  detailing the 
Rb1
ΔPP1
 targeting construct in relation to the Rb1 locus (Chau et al., 2002). A 12 kb 
portion of the 3‟ end of the Rb1 allele was used as a means to facilitate homologous 
recombination, allowing for integration of our mutation into the Rb1 gene. The 
R869F/F870R mutation was inserted into exon 25 along with an EcoRI restriction 
enzyme digest site in intron 24. The addition of this EcoRI site allows for differentiation 
between targeted alleles and wildtype alleles when performing the Southern blot 
screening. A PGK-Neo cassette flanked by LoxP sites was then inserted into intron 25 to 
75 
 
allow for neomycin selection of mouse embryonic stem cells with integration of the 
targeting vector into the mouse genome. The completed targeting vector was linearized 
using a NotI restriction digest and provided to the London Regional Transgenic and Gene 
Targeting facility where this construct was electroporated into mouse embryonic stem 
cells with clonal expansion of the neomycin resistant cells. 
4.2 Southern Blot Screening Lead to a Small Selection 
of Potential Targeted Clones 
To determine whether mESC clones had properly incorporated the Rb1
ΔPP1
 targeting 
construct into the mouse genome, I performed Southern Blot screening to determine 
proper targeting of the Rb1 locus. 180 mESC clones which had been expanded and 
selected in neomycin were used for Southern blot screening, with genomic DNA isolated 
from each clone. Genomic DNA for each clone was digested using the HindIII restriction 
enzyme and electrophoresed on an agarose gel. Following transfer onto a nitrocellulose 
membrane, a radiolabelled probe for Exon 24 of the mouse Rb1 gene was used as a 
probe. Membranes were then washed and exposed for autoradiography and images were 
developed. Presented in Figure 4.3A is a representative blot of screening using the Exon 
24 probe with the HindIII restriction digest and from this blot we can observe that the 
clones labeled 1-5F and 1-2D both show a doublet of bands. Clone 1-2D shows the 
expected bands at 6 kb and 9 kb indicating a properly targeted clone. Clone 1-5F had an 
observable pair of bands, though it appears that the bands were at higher than the 
expected size. This aberrant size of the observable doublet could have been due to 
unusual migration of digested DNA due to contaminates in the DNA, such as excess 
salts. Further screening was carried out and as shown in Figure 4.3B, clone 4-4A when 
digested with HindIII and subjected to Southern blot analysis with the Exon 24 probe, 
produced an observable doublet of bands at 6 and 9 kb. This doublet pattern again is 
representative of the correct size distribution expected from a correctly targeted Rb1 
locus. From this comprehensive screening of 180 mESC clones, two clones offered 
potential as correctly targeted clones. These candidate clones, along with others, were 
selected to be regrown from cellular stocks to be subjected to more rigorous screening to 
confirm the presence of the Rb1
ΔPP1
 allele. 
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Figure 4.1: The Rb1
ΔPP1
 Mutation and Schematic of Targeting for Rb1
ΔPP1
 Gene 
Targeted Mice 
A) General schematic for the process of generating a gene ES line that would contain the 
ΔPP1 mutation in the Rb1 gene. B) Schematic depicting the potential molecular 
consequence of this mutation on the pRb protein. 
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  Figure 4.2: Schematic of Targeting for Rb1
ΔPP1
 Mutation in the Rb1 Locus 
Following electroporation of 129 ES cells with the targeting construct, clones were 
screened by Southern blotting. Initial screening of ES clones was carried out using a 
HindIII digestion to give a wildtype fragment of 6 kb versus 9 kb for targeted alleles. B-
BamHI, H-HindIII, R-EcoRI, S-SacI,  25*-Exon 25 with ΔPP1 mutation, 25- Exon 25, 
26-Exon 26, 27- Exon 27 
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Figure 4.3: Screening of mESCs with Southern Blotting for Incorporation of the 
Rb1
ΔPP1
 into the Rb1 Locus 
Incorporation of the ΔPP1 mutation into the Rb1 locus, through homologous 
recombination, was determined by Southern blotting. A) A representative image shows 
southern blot screening using the Exon 24 probe and a HindIII digest. B) A 
representative image shows Southern blot screening using the Exon 24 probe and a 
HindIII digest.  N =1 for both Southern blots presented in this figure.  
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4.3 Confirmation Screening of Candidate mESC 
Clones Showed No Correctly Targeted Clones 
To ensure that our candidate mESC clones were in fact targeted and usable for blastocyst 
injections, a more rigorous round of screening was performed to confirm our results from 
the mass screenings. The indicated mESC clones were regrown in neomycin selection 
medium and genomic DNA was extracted. Southern blot screening was carried out as a 
means to confirm proper single integration of the targeting construct into the mouse Rb1 
locus. Southern blots were performed using genomic DNA digested with HindIII 
restriction enzyme and probed using a radiolabeled probe corresponding to the neomycin 
resistance cassette. From this screening, we observed that the candidate clones showed 
single integration of the neomycin cassette into the mouse genome (Figure 4.4). With this 
result, I then set out to carry out the confirmation screening using the Exon 24 probe with 
the HindIII digest and a EcoRI digest. As shown in Figure 4.5A, when the HindIII digest 
was carried out and the radiolabelled Exon 24 probe was used in Southern Blot screening 
of the three indicated mESC clones, it can be observed that all three clones showed the 
presence of only the 6 kb band, which corresponds to the wildtype Rb1 locus. In 
coordination with this screening, the EcoRI digest was performed and Southern blot 
analysis was performed using the Exon 24 probe which is presented in Figure 4.5B. From 
analysis of this Southern blot we observed that all three clones displayed a band at 
approximately 20 kb. This 20 kb fragment corresponds to the wildtype Rb1 locus, 
whereas a correctly targeted clone would have a 9 kb fragment when subjected to 
Southern blotting with the Exon 24 probe and the EcoRI digestion. From these results, we 
can conclude that of the three candidate clones isolated from our initial mass screening of 
180 mESC clones, none were in fact correctly targeted when subjected to this second 
round of more rigorous screening. 
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Figure 4.4: Single Integration of the Neomycin Selection Cassette in Candidate 
Clones 
Single incorporation of the Neomycin selection cassette, through homologous 
recombination, was determined by Southern blotting. Southern blotting using the 
Neo probe following HindIII restriction digest of isolated genomic DNA was 
performed for mESC clones which had been selected for confirmation screening. 
Potential candidate clones are indicated.  N = 1 for Southern blot screening 
presented in this figure.  
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  Figure 4.5: Confirmation Southern Blot of Three Potentially Targeted mESC 
Clones 
Selected mESC clones were regrown and genomic DNA was isolated and southern blot 
screening was carried out to determine if potential clones were correctly targeted. A) The 
indicated mESC clones were digested with HindIII and southern blot was performed 
using the exon 24 probe. B) The indicated mESC clones were also digested with EcoR1 
and southern blot was performed using the exon 24 probe. N = 1 for Southern blot 
screens performed in this figure.  
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5 Discussion 
5.1 Summary of Findings 
The retinoblastoma protein has been extensively studied in regards to post-translational 
modification primarily through phosphorylation by CDKs. More recent work has begun 
to emerge in the field that has begun to focus on other post-translational modifications of 
pRB and the potential for added complexity in regards to the multitude of pRB functions. 
One potential means for further regulation of pRB function may lay in acetylation in the 
C-terminus of pRB at lysine residues 873 and 874(Chan et al., 2001). These particular 
lysine residues lie directly in a binding domain for both Cyclin/CDKs and PP1(Hirschi et 
al., 2010).  I hypothesized that the regulation of pRB dephosphorylation is critical in 
regulating pRB function and activity and that acetylation of lysines 873 and 874 in the 
pRB C-terminus may play a role in the regulation of pRB dephosphorylation. From the 
work presented in this thesis, I have shown the generation of an acetyl K873/K874 pRB 
antibody which specifically detects acetylation of K873/K874 in the pRB C-terminus 
through the use of in vitro assays. Through the use of these assays I was able to 
demonstrate that CDK2 kinase activity towards pRB, which had been acetylated at 
K873/K874, was in fact reduced when compared to unmodified pRB. In vivo assays that 
were used to isolate conditions where acetyl K873/K874 pRB has been suggested to 
occur, such as DNA damage, were then assessed to act as positive control conditions for 
future work(Carnevale et al., 2012; Markham et al., 2006). From the results presented in 
Figures 3.9-3.11, we interpret that with our antibody, we were unable to detect acetylated 
K873/K874 pRB through enrichment of pRB or through association with E2F1 under 
either asynchronous or DNA damage through double stranded breaks.  
 Regulation of phosphorylation of the retinoblastoma protein has largely been 
studied by the means of regulating Cyclin/CDK phosphorylation of pRB. Recent work 
from our lab though has uncovered an overlapping CDK and PP1 binding domain in the 
C-terminus of pRB. This overlapping binding site offers a novel and compelling means of 
discrete regulation of pRB, by the means of competitive access between the respective 
kinase and phosphatase. From previous work in our lab, a mutation in this binding site 
was uncovered that was able to specifically disrupt PP1 binding to pRB without 
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disrupting CDK binding to the pRB C-terminus. This mutation in the pRB C-terminus is 
distinguished as the pRB
ΔPP1
 mutation and allows for discrete study of pRB 
dephosphorylation uncoupled from CDK phosphorylation. In this thesis, I detailed work 
outlining the construction and generation of a targeting construct that would allow for 
gene targeting of the mouse Rb1 locus with the pRb
ΔPP1
 mutation. As presented and 
shown in this work, through Southern blot screening, we were able to see clones that 
appeared to be targeted but through screening confirmation using regrown mESC clones 
and southern blotting, these clones appeared to lose the targeted allele.  
 As mentioned previously in my introduction, the study of pRB dephosphorylation 
has been characterized previously in the literature but to a much lesser extent than CDK 
phosphorylation of pRB. This work though has typically lacked insights into how 
phosphatases are specifically recruited to act on pRB, in particular cellular contexts of 
stress distinctively highlight our lack of understanding into the mechanistic basis of pRB 
dephosphorylation. The work highlighted in this thesis is a novel approach in regards to 
studying pRB with respect to dephosphorylation, particularly through a study of post-
translational modification and the PP1/CDK binding site within pRB. This study helps us 
to gain further insight into the process of dephosphorylation, and highlights the 
regulatory elements such as the PP1 C-terminal docking site and pRB acetylation that 
may play an important role in this process.  
5.2 Acetylation of pRB  
Our observations in respect to the lack of pRB acetylation at K873 and K874 in vivo 
through western blotting using our anti-acetyl K873/K874 pRB antibody was a stark 
contrast to the reported literature findings. A critical examination of the body of literature 
with respect to pRB acetylation at K873 and K874 though may provide insights in 
regards to our observations. Previous work including (Chan et al., 2001) regarding 
acetylation of pRB identified lysine residues 873 and 874 as acetylation sites through 
similar in vitro acetylation assays. The observations noted in Chapter 3 of this thesis are 
similar to those documented by Chan and colleagues, including the need to selectively 
purify acetylated pRB substrate to demonstrate biochemical effects such as reduced CDK 
phosphorylation. Interestingly from this work, experiments confirming that these sites 
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were indeed present in vitro are lacking substantial in vivo verifcation to confirm that 
K873 and K874 are the acetylation sites responsible for the observed effects. Most in vivo 
experiments used to confirm the presence of these modifications are reliant on the use of 
immunoprecipitations and western blotting using pan-acetyl-lysine antibodies, similar to 
those presented earlier in this work. Anecdotally, these antibodies appear to be 
challenging to present reliable data that can be easily interpreted by the user, which can 
be noted from discrepancies of Western blots presented in Figure 3.5B and Figure 3.6 
with regards to western blots with anti-acetyl lysine antibodies. Most of the previously 
discussed work in the literature is also limited to transfection based experiments 
involving isolation of tagged pRB populations and western blotting with acetyl lysine 
antibodies. These experiments highlighted from previous reports raise the questions of 
how representative these experimental conditions are to more physiological experiments. 
As discussed in the introduction, various proteomic approaches have highlighted multiple 
acetylation sites throughout pRB. These acetylation sites in pRB could have been falsely 
attributed to acetylation at K873 and K874 primarily due to most experiments having to 
rely on acetyl-lysine antibodies for detection of K873/K874 acetylation. This ambiguity 
regarding the exact conditions of K873/K874 acetylation leads to the obvious question of 
whether the conditions we attempted to observe this set of modifications, specifically 
DNA damage signalling induced  by double stranded breaks, were in fact the best choice 
to find this set of modifications. While the work of Markham and colleagues (Markham 
et al., 2006) suggest that pRB under DNA damage is acetylated on K873/K874 and 
promotes association with E2F, other work has shown more generalized results attributed 
to acetyl lysine blots or association with acetyltranferases including p/CAF (Carnevale et 
al., 2012; Ianari et al., 2004; Ianari et al., 2009). The later reports again leave open the 
possibility that in fact acetylation of pRB observed under DNA damage scenarios could 
be attributed to other sites in pRB or in fact other proteins involved in large protein 
complexes. A further layer of complexity regarding K873/K874 acetylation lies in the 
lack of proteomic evidence for K873 acetylation under the admittedly limited conditions 
investigated, as well as these studies showing no occurrence of both K873/K874 on pRB 
peptides analyzed. This ambiguity that underlines the prior literature draws into question 
86 
 
whether K873/K874 acetylation is in fact present under the conditions of DNA damage 
that we examined or in fact whether both lysine residues are in fact acetylated in vivo.  
5.3 Lack of K873/K874 Acetylation of pRB In Vivo 
Under DNA Damage with Acetyl-K873/K874 Antibodies 
The lack of commercial reagents towards K873/K874 acetylation has further hampered 
their study, with present knowledge suggesting one other group attempting to generate 
any type of antibody against this set of modifications. Prior work by Markham and 
colleagues (Markham et al., 2006) demonstrated the production of a similar antibody 
against this modification, though work using this antibody is limited to 
immunofluorescence and western blotting with mixed results. Our hypothesis that pRB 
phosphorylation could be regulated through the acetylation of K873 and K874 through 
acetylation motivated us to generate a specific antibody against the combination of 
acetylated K873/K874. Through the in vitro work presented to characterize our 
antibodies against acetylated K873/K874 demonstrated specificity for the tandem 
acetylation by means of Western blotting, we were unable to detect acetylation with our 
in vivo experiments. One explanation for this is technical limitations of the presented 
experiments in this work, either through scale of the experiment with respect to amounts 
of material used or limits of detection of substrate in regards to western blotting. Ideally, 
future experiments involving mass spectrometry using cells that have been subjected to 
DNA damage would be the best scenario to test for the presence of K873/K874 pRB 
acetylation and whether these modifications occur in tandem.   
The lack of evidence for pRB acetylation at K873 through proteomic approaches 
compared to the more targeted approaches to studying post-translational modifications 
creates a conflict of whether in fact K873 is acetylated in physiological paradigms. 
Further analysis of K873 presents literature that acts to further confound this issue, as 
pRB has been shown previously to be methylated on K873 and not on K874(Munro et al., 
2010). While DNA damage conditions are not specifically analyzed in this report for 
K873 methylation, the author‟s report that methylation at this site seems to be a 
requirement of proper in vitro myoblast differentiation and senescence of cells. The 
requirement of K873 methylation in myoblast differentiation mimics a prior report 
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(Nguyen et al., 2004) that states K873/K874 acetylation is required for myoblast 
differentiation. With similar conditions attributed to both modifications, this prompts us 
to speculate whether prior results of K873/K874 acetylation observed under DNA 
damage could in fact be K873 methylation with K874 acetylation. Thus the possibilities 
that under DNA damage, pRB could be acetylated at only K873, methylated at K873 or a 
combination of both modifications could be present on pRB in this scenario. The 
circumstances where different single site modifications or combinations of acetylation 
present obvious issues in regards to our generated antibody. At this time, we are unable to 
rule out whether our acetyl K873/K874 pRB antibody  is able to detect instances where 
only K874 is acetylated, K873 is methylated or the possible instance where K873 is 
methylated and K874 is acetylated. To further elucidate the specificity of our generated 
antibody against these specific combinations of post-translational modifications, one 
could envision performing similar ELISA experiments highlighted in Figure 3.5, with a 
range of synthetically modified peptides baring the various combination of modifications 
to test whether our antibody is able to recognize these epitopes. The generation of a panel 
of antibodies against the different combination of modifications and performing similar 
experiments against DNA damaged cells would be worthwhile to further explore whether 
these combination of modifications are responsible for the previously reported studies. 
The work outlined in this thesis helps us to further build an understanding of the intricate 
nature of post-translational modifications in regards to pRB. While historically pRB has 
been regarded for the general system of widespread phosphorylation by CDKs, even this 
paradigm has begun to be challenged. As summarized in recent review articles, work in 
the field has led to the emergence of a host of post-translational modifications of pRB 
that could act in concert to regulate the multitude of pRB functions (Macdonald and 
Dick, 2012; Munro et al., 2012). With the emergence of better analytical techniques and 
proteomic approaches to study post-translational modifications of proteins, we are 
beginning to see the higher order complexity involved in managing and regulating the 
wide cascade of post-translational modifications. This work begins to outline acetylation 
of pRB at K873 and K874 in the pRB C-terminus and the potential for a much more 
complicated system of post-translational modifications that may be context dependent.     
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5.4 Attempted Creation of the Rb1ΔPP1 Gene 
Targeted Mouse 
In chapter four of this thesis, I detailed work to produce a targeting construct to generate 
gene targeted mice which harboured a mutation in pRB which we deem the ΔPP1 
mutation. This mutation in pRB has been previously characterized in our lab to disrupt 
Protein Phosphatase 1 binding in the C-terminus of pRB in a region where Cyclin/CDKs 
have been shown to bind pRB without disrupting Cyclin/CDK binding (Hirschi et al., 
2010). This mutation presented us with a unique means of studying the process and 
regulation of pRB dephosphorylation in an in vivo model system. Much of the work to 
date characterizing pRB dephosphorylation in vivo has relied on drug treatments targeting 
phosphatases, leaving the direct consequences of deregulated pRB dephosphorylation 
difficult to interpret due to the wide swath of cellular functions attributed to protein 
phosphatases (Moorhead et al., 2007). Thus our approach of generating a gene targeted 
mouse disrupting PP1 binding to pRB would allow us to study the consequences of pRB 
dephosphorylation in isolation with respect to other PP1 cellular functions   
 Through construction of our Rb1
ΔPP1
 targeting construct we envisioned the ability 
to isolate mESC clones which harboured our mutant allele of pRB. The strategy used to 
build our targeting construct was based off work in the Wang lab, which generated a gene 
targeted mouse targeting residues in exon 25, similar to our mutation (Borges et al., 2005; 
Chau et al., 2002). This gene targeted mouse, along with pRB gene targeted mice 
established in our lab had no issues with viability and are able to create viable mice, thus 
we hypothesized there would be no issues with the allele recombination and that these 
mice would be viable(Cecchini et al., 2014; Isaac et al., 2006). Through Southern blot 
analysis of mESC clones electroporated with our targeting construct, our initial screening 
identified two candidate clones which appeared to have proper targeting of the Rb1 gene. 
When our confirmation screening was carried out, surprisingly we found that our three 
clones appeared to not have the targeted allele. 
 These results were surprising to us as we had expected little to no issue with 
generating the targeted mESC cells based on prior experiences in our lab and as well as 
work done by the Wang group, as outlined in the preceding paragraph. While we cannot 
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provide definitive reasons for the odd behaviour exhibited through our work targeting the 
PP1 binding site within pRB, I offer up some speculative and circumstantial reasoning 
why this phenomenon was observed in our hands. Recent literature that emerged during 
screening of our mESC clones highlights the potential regulatory role of pRB in stem 
cells. From this work, though mostly done in hESCs, presented the idea that inactivation 
of pRB forces hESCs to either undergo differentiation or have apoptotic programs 
activated. Furthermore, the authors suggest that a pool of hypophosphorylated or active 
pRB is maintained, even in systems where hESCs are still proliferating and maintaining 
stem-like qualities (Conklin et al., 2012; Sage, 2012). The introduction of our pRBΔPP1 
mutation into mESC cells, with the effect of disrupting the dephosphorylation of pRB and 
subsequent activation may have a much larger role in this cell population than initially 
thought of by disrupting the balance of pRB activity required in these cells. The 
disruption of this small pool of activated pRB may have the unintended effect of forcing 
these cells to differentiate or in fact promoting apoptosis in these cells, hindering our 
ability to clonally expand and isolate correctly targeted cells.  
 As previously mentioned above, the targeting strategy for our allele was adopted 
from the method used by the Wang lab to develop mice which removed a caspase 
cleavage site in this region of pRB(Borges et al., 2005; Chau et al., 2002). One detail that 
initially was not considered when creating this construct was the orientation of the 
neomycin cassette used for selection of targeted cells in our system. The method used by 
the Wang lab when constructing their construct left the Neo cassette in the same 
orientation as the Rb1 gene, allowing both the pRb transcript and the Neo transcript. This 
production of the pRb transcript and subsequent protein product allows for the active 
expression of our mutant protein in the mESC cells, whereas the alternative orientation of 
the Neo cassette would primarily have Neo transcript produced without mutant pRb 
transcript. Thus in our system, pRbΔPP1 protein could be expressed in our mESC cells 
during initial selection. The expression of the mutant pRb in this context could easily be 
envisioned to create a disruption in the balance of inactivated hyperphosphorylated pRB 
versus activated hypophosphorylated pRB in these mESCs that were in fact correctly 
targeted. This imbalance could be predicted to lead to either cells being selected for 
differentiation or for apoptosis. This would mirror the effects we observed where as we 
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continued to passage the potentially targeted mESC clones, we lost the targeted allele 
when genomic DNA was analyzed using Southern blots.  Thus we could speculate that 
this loss of the targeted allele could be attributed to positively targeted cells undergoing 
differentiation or apoptosis, and thus being lost over subsequent passages. 
 From this speculation into our failed targeting of the pRbΔPP1 mutant, some 
identifiable caveats to our targeting have potentially emerged that could be mitigated to 
some degree. One potential means of allowing for easier targeting would be to reverse the 
orientation of the Neomycin cassette, thus restricting the ability for our mutant allele to 
be transcribed until later stages of the process, where targeted mice are bred with mice 
expressing Cre recombinase which cleaves the LoxP elements to remove the Neo 
cassette.  
 This work detailing our attempts to generate the pRbΔPP1 mouse model to study 
targeted disruption of PP1 binding to pRb and potentially deregulating pRb 
dephosphorylation offers a potentially exciting insight into this relatively understudied 
process in regards to pRb function. From our results, it may appear that regulation of PP1 
binding in pRb by means of the C-terminal binding site within pRB may be critical to 
mESC and potentially all stem like cells.  
5.5 Conclusions 
The work presented in this thesis help to begin to elucidate potential means of regulating 
pRB dephosphorylation, which is a critical process in activating pRB, specifically in 
scenarios such as DNA damage. The work presented here in regards to acetylation of 
pRB at K873 and K874 which lie in a binding domain for PP1 with pRB, potentially 
show a much greater complexity than initially reported. While the potential post-
translational modification regulatory system for the PP1 and CDK binding domain may 
be more complicated than initially hypothesized, the need to understand regulation of this 
site may be critical in regards to fully understanding PP1 mediated dephosphorylation of 
pRB. From our work described within this thesis to generate a gene targeted mouse 
model to examine disruption of the PP1 binding site in pRB, we have potentially isolated 
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a critical means of controlling pRb dephosphorylation and activation that when perturbed, 
may have deleterious effects in mESC stem cells.  
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